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ABSTRACT
CHARACTERIZATION OF HUMAN T-CELL LEUKEMIA VIRUS 1 REVERSE
TRANSCRIPTASE
Pinky Gundayao Agbuya
Old Dominion University and Eastern Virginia Medical School. 2000
Director: Dr. Laura K. Moen

Human T-cell leukemia virus 1 (HTLV-1) is a type C human retrovirus which has
been the causative agent o f Adult T-cell leukemia. Replication o f the retrovirus requires
a reverse transcriptase which converts the retroviral RNA into DNA which is later
incorporated into the host's genome. Very little is known about the reverse transcriptase of
HTLV-1. Researchers have attempted to purify HTLV-1 RT by isolating the enzyme from
human cell lines. Because large amounts o f protein could not be produced by this isolation
method, the reverse transcriptase cannot be fully characterized. In this research, a
recombinant protein expressed in E. coli was purified, which has an apparent molecular
weight consistent with that from virion-derived reverse transcriptase. This recombinant
protein was purified to approximately 90% homogeneity by a two-step chromatographic
process on phosphocellulose and sepharose CL-6B.
The reverse transcriptase o f HTLV-1 is synthesized as a Gag-Pro-Pol precursor
protein and undergoes proteolytic processing during maturation. By using sequence
comparisons from a number o f retroviral po l genes as well as information about the
location o f the ribosomal frameshift, the location o f the putative coding sequence for the
enzyme has been identified. This information and PCR amplification was used to
construct a clone, which spans a region o f the pro-pol junction o f HTLV-1. for
overexpression in £. coli. The Pro-Pol protein was processed in vitro with a recombinant
HTLV-1 protease to mimic the proteolytic processing o f the Gag-Pro-Pol precursor in the
virion. SDS-PAGE analysis o f the cleavage sample revealed a 5.5 kDa fragment. This
processed fragment o f the Pro-Pol protein was further treated with trypsin and analyzed
by capillary LC-MS and MS/MS. Analysis o f the fragment by MS/MS revealed the Nterminal cleavage at LeuI57-Prol5S o f the pro ORF. These results confirm the authentic
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amino acid sequence o f the reverse transcriptase o f HTLV-l RT. The data reported here
provides a basis for further investigation o f the functional and structural aspects o f
protein-nucleic interaction of the enzyme.
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CHAPTER I
INTRODUCTION

Human T-cell Leukemia Virus 1 (HTLV-1) is a type C human retrovirus initially
reported to be the causative agent o f Adult T-cell leukemia (39-40. 96. 117. 136-138).
The virus was first isolated in 1980 by Poiesz et al. from a cell line derived from a patient
with Adult T-cell Leukemia (ATL) (14, 35). ATL is a mature T-cell non-Hodgkin
lymphoma with a leukemic phase characterized by circulating CD47CD25" T-cells (134).
We now know that HTLV-1 infection has a much broader spectrum o f disease
manifestations including HTLV-1 associated myelopathy, tropical spastic paraparesis
(HAM/TSP) (28. 38. 90. 100-101. 112, 120). uveitis (79) and an infectious dermatitis in
children (60). Several inflammatory and immune-mediated conditions such as
polymyositis, arthropathy. Sjogren’s syndrome, and facial nerve palsy have been
associated with HTLV-1. although, a clear etiolgoical relationship has not been
established (7.48, 128).
While the pathogeneses o f these diseases is unknown, all involve activated.
HTLV-1 infected CD4' T-cells. The human T-cell lvmphotropic virus resides in and
functionally alters immune cells o f central importance for immunoregulation. Thus,
infection o f CD4' T-cells (immune cells) by HTLV-1 has several influences on the
immune response: (1) interference with signaling pathways and transcriptional
regulation: (2) activation o f resting T-cells which propagates the infection: (3) activation
ofCD8~ cytotoxic T-lvmphocytes (CTLs) which alters cell death pathways in the host Tcell; and (4) induction o f a strong antiviral immune response, which nonetheless is
incapable o f eradicating the infection (44).

EPIDEMIOLOGY OF HTLV-1
Worldwide, HTLV-1 infects between 11 and 20 million people. The infection is

The model for this dissertation is Archives o f Biochemistry and Biophysics.
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endemic in Southern Japan, the Caribbean basin (10). parts of South America (4), parts
of Africa (19, 143), the Middle East, the Pacific Melanesian Islands (150) and Papua New
Guinea. The prevalence in these endemic populations ranges from 5-30% (88. 93. 141).
The seroprevalence among low-risk populations, such as those o f the southern United
States, is estimated to be 0.025% (70. 144). Patients who acquire HTLV-1 are at risk o f
developing both infectious and noninfectious sequelae. Seropositive individuals have a
0.1 to 1.0% risk o f developing HTLV-l associated myelopathy/tropical spastic
paraparesis (HAM/TSP) (133). HAM is a chronic progressive inflammatory
demyelinating myelopathy, often clinically confused with multiple sclerosis, that
typically presents 10 to 30 years after infection with lower limb weakness, profound
bladder dysfunction and minimal sensory loss.
Seropositive individuals have a 1 to 4% lifetime risk o f developing ATL (133).
Disease manifestations occur after a latent period and are classified by clinical and
laboratory criteria as acute, chronic, lymphoma or smoldering ATL. Widespread or
localized skin lesions such as large nodules, plaques, ulcers and a generalized papular
rash are common. Immunosuppression is well documented, manifesting as bacterial and
opportunistic infections which contribute to a poor prognosis (37, 120. 140).
Infectious dermatitis has been reported from several HTLV-1 endemic
populations including Japan, Trinidad. Brazil, and Columbia. The disease is
characterized by a severe exudative dermatitis o f the scalp, external ear and retroauricular
aras, eyelid margins, paranasal skin. neck, axillae, and groin as well as generalized tine
papular rash. The incidence and prevalence o f this disease are undefined, as is the
pathogenesis (61. 151).
Idiopathic uveitis was observed to be very common in the HTLV-1 endemic areas
of Kyushu. Japan, leading to speculation that HTLV-l infection might be the cause (7980). Patients with HTLV-1 associated uveitis will often complain o f blurred or foggy
vision and acute, sudden onset o f floaters. Blurred vision is associated with acute onset
o f mild inflammation in the vitreous body followed by mild iritis and retinal vasculitis.
HTLV-1 is, thus, the causative agent in clinical disorders affecting several organ
systems. Excess morbidity and mortality have recently been reported among carriers (3)
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indicating that the full public-health impact o f HTLV-1 may be much greater than
generally perceived.

MODES OF TRANSMISSION
The virus may be transmitted both horizontally through blood products, sexual
contact and shared needles and vertically through breast milk, transplacentally, and
intrapartum. O f these modes o f virus transmission, transfusion is perhaps the most
efficient: the probability o f seroconversion in the recipient o f contaminated blood is 4060% (74. 89). HTLV-1 transmission by blood products can lead to rapid development of
HAM or TSP and has been seen within 6 months o f transmission (35). Today, routine
blood-donor screening for antibodies to HTLV-1 is performed in the USA and other
countries.
Most HTLV-1 infections are attributable to transmission from mother to child
through prolonged breastfeeding or transmission by sexual contact later in life. Motherto-child transmission o f HTLV-1 occurs primarily through ingestion o f milk-borne
lymphocytes (142) whereby transmission efficiency is dependent on duration o f breast
feeding and the presence o f maternal antibodies to HTLV-1.

METHODS OF DETECTION
The identification o f HTLV-l by the detection o f antibodies in infected
individuals is important because knowledge o f HTLV-l seropositivity may help to
prevent the transmission between sexual partners, as well as transmission from mother to
child and blood transfusion. Detection o f antibodies to HTLV-1 is useful in establishing
a diagnosis o f ATL. HAM/TSP and other HTLV-1-associated diseases, and for screening
o f blood donors and pregnant women. Methods to detect HTLV-1 antibodies include
gelatin particle agglutination (PA), indirect immunofluorescence (IF), immunoperoxidase
staining (IP), enzyme-linked immunosorbent assays (ELISA) with disrupted whole virus,
synthetic peptides or recombinant proteins, radioimmunoprecipitation assay and Western
blotting (73. 147).
ELISAs using whole virus lysate are the most commonly used screening assays
for human sera or plasma in the United States and Europe. In Japan, the particle

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

4

agglutination assay is most commonly used for screening. Guidelines from the US Public
Health Service and other international groups (78) recommend that newly identified
seropositive individuals have additional blood collected for repeat testing to eliminate
possible technical errors. IF. IP, radioimmunoprecipitation assay (RIPA) and Western
Blotting (WB) assays are commonly used as supplementary assays to confirm specificity
o f the antibodies to HTLV-1. The most common WB assays are constructed from whole
virus lysate with the addition of recombinant envelope antigens and/or HTLV-1 and
HTLV-2 specific envelope peptides to distinguish HTLV-1 to HTLV-2. HTLV-2 shares
a 60% amino acid homology with HTLV-l (24. 121). Consequently, it is difficult to
distinguish the two unless virus-specific reagents are used. TTiis distinction is important
because HTLV-2 is less pathogenic than HTLV-1 (63).
Additionally, DNA analysis is used to diagnose ATL and other HTLV induced
disease. Specifically, the polymerase chain reaction (PCR) has been used to identify
type-specific proviral sequences in peripheral blood mononuclear cells from infected
individuals to distinguish HTLV-1 from HTLV-2 and to detect DNA in tumor tissue and
other biological specimens (95. 106).
Because HTLV-1 does not need a specific receptor for infection, it not only
infects lymphocytes but also a variety o f other cells. After infection. HTLV-l randomly
integrates its provirus into the chromosomal DNA. Since ATL cells show clonal
proliferation in HTLV-1 infected T-lymphocytes. the demonstration o f clonal integration
o f the HTLV-1 provirus is essential for the diagnosis o f ATL (148). Southern blot
analysis is used to identify the clonal proliferation o f HTLV-1 cells. However. Southern
blot analysis requires 5% infected cells for detection (147). The PCR method is much
more sensitive, yet. it cannot distinguish whether HTLV-1 infected cells proliferate
monocionally or polyclonally. Inverse PCR (IPCR) enables the identification of
unknown sequences flanking known sequences such as retroviral DNA. (76, 132).
Therefore. IPCR is used to detect the monoclonality o f HTLV-1 infected cells.

RETROVIRAL REPLICATION
A virus is a life form that lacks its own metabolism, and is therefore dependent on
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FIG. 1. Retroviral life cycle. The virus particle attaches to the host cell and through the
catalytic activities o f retroviral enzymes, a new virus is produced.
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the metabolic apparatus o f a host cell for its replication. The core structure o f a retrovirus
contains its genetic code in two RNA molecules. In addition, each virus particle contains
enzymes and other proteins that are required for infection o f host cells and conversions o f
them to virus factories. The surface o f the virus particle contains glycoprotein molecules
that mediate attachment o f the virus to a receptor protein (CD4 ) located on the plasma
membrane o f the infected cell (Fig. 1). Upon entry into the host cell, the subviral complex
containing the genomic RNA molecules and limited viral proteins is released into the
cytoplasm (124). Single-stranded RNA chains are converted to double-stranded DNA by
the enzyme, reverse transcriptase. The double-stranded DNA is then integrated into the
host genome by another enzyme, integrase. to form the provirus.
The viral proteins take over the control functions o f the host cell and can start
making new viral particles. The reverse transcriptase enzyme o f the host cell starts to
produce multiple copies of messenger RNA encoding new viral materials. Translation of
the mRNA results in the production of long peptide chains. The long peptide chains or
polypeptide precursors and viral RNA are then exported to budding particles that form on
the cell surface. Completion o f the virion occurs by pinching off the budding particle at the
cell surface. In the last stage o f budding, the polyprotein precursors are proteolvtically
cleaved at domain boundaries by the viral protease to liberate mature proteins.

MOLECULAR ORGANIZATION OF HTLV-1
As previously stated, HTLV-1 has been associated with a wide spectrum o f
clinical manifestations including cancer, immunological manifestations and neurological
disorders. Because o f its clinical relevance, the genes o f the retrovirus have become a
focal point o f retroviral research for scientists today. As depicted in Fig. 2. the viral
genome o f the HTLV-1 pro virus consists o f two long terminal repeats (LTR), the typical
gag, pro. pol. and env genes, and a novel 3‘ end which encodes the two trans-regulatorv
proteins, tax and rex (120-121).
The LTR enables the genome to insert itself into the genome o f a host cell. In the
proviral DNA. the LTR contains signals which control and affect transcription, splicing,
and packaging o f RNA into virions.
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The gag and env genes are known to be essential for the production o f infectious
progeny virus, in that, they encode proteins that constitute the virus structure. The gag
gene encodes structural proteins, specifically the core proteins p 19 (matrix protein) and
p24 (capsid protein). The protease is primarily responsible for processing o f the gag gene
products. The pol gene, located between the gag protease genes and the env gene (52).

LTR

LTR
gag
pro
pol

env
tax
rev

FIG. 2. HTLV-1 genome. Long terminal repeats (LTR) and open reading frames are
depicted.

) denotes frameshift sites.

includes an RNA-directed DNA polymerase, the reverse transcriptase, an RNaseH region
which degrades viral RNA in the immediate wake o f its reverse transcription and an
integrase or endonuclease region which integrates the newly synthesized DNA into the
host genome.
The env gene encodes the precursor envelope protein. gp61. G p61 is cleaved by
an unknown cellular enzyme to yield the small transmembrane (gp2l) and large external
envelope (gp46) glycoprotein. Gp46 interacts with a still unidentified cellular receptor to
facilitate viral entry (22).
There exists a long ORF between the env gene and the 3*-LTR which is called the
pX region. Double spliced mRNA enables this region to encode two regulatory genes,
tax and rex. These regulatory genes are essential in controlling viral RNA and protein
synthesis (86). Expression products o f these genes yield proteins not present in the virus
itself. The Tax protein is located in the nucleus and enhances viral transcription by
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activation o f three 21 base pair enhancer elements located in the U3 region o f the viral
LTR (155). Tax does not actually bind to this region, rather, it activates different cellular
transcription factors that in turn bind to this region. IL-2a and its receptor are responsive
to transactivation by Tax and expression o f this receptor in HTLV-1 transformed cells has
been reported (22). The Tax protein also activates sequences to which the nuclear factor
kB

(NF k B) binds and thereby may induce a set o f genes expressed during T-cell

activation.
The Rex protein is also located in the nucleus and functions in regulating the
levels of unspliced to spliced viral mRNA. Rex is responsible for exporting full length
gag/pol mRNA and single spliced env mRNA from the nucleus to the cytoplasm (55.
106). Export of mRNA is achieved by binding o f a phosphorvlated Rex protein to cisacting RNA sequences . called the rex responsive elements in the viral RNA (4. 8. 11,3.
119. 152). The Rex protein is therefore regarded as a positive regulator o f expression o f
structural proteins o f HTLV-1. However, an overexpression o f rex may lead to negative
regulation. Thus. HTLVs possess a self-regulatorv mechanism to control their replication
by products of the tax and rex genes (49).

RIBOSOMAL FRAMESHIFTING
All o f the genes in the retroviral mRNA produce proteins essential for the surviv al
o f the virion. However, not all virion particles that are produced are infectious. The
proteins translated from the mRNA in the nucleus are long polypeptide chains or
polvprotein precursors which are transported to the cell membrane and incorporated in
the virion. The budding virion is not considered infectious until the protease cleaves the
polyproteins into their respective structural proteins. The mature virion components are
generated by proteolytic cleavage o f the primary translational products o f the genome
sized mRNA. designated the Gag, Gag-Pro. Gag-Pol, and Gag-Pro-Pol polyproteins. The
synthesis o f Gag-Pro, Gag-Pol, and Gag-Pro-Pol fusion proteins, which all share the
common gag initiator codon located at the 5'end o f the gag gene, is translationally
regulated. Two general mechanisms by which the synthesis o f the fusion proteins can be
achieved are known: readthrough suppression and ribosomal frameshifting.
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In readthrough suppression, an amino acid is inserted (by a suppessor tRNA)
where a stop codon is located. Through the actions o f these suppressor tRNAs, some
ribosomes are able to bypass the designed stop codon during translation o f the mRNA
and a fusion protein is produced instead o f the Gag polyprotein.
In mammalian type C retroviruses, the gag amber terminator (UAG) is suppressed
by a glutamine-tRNA to translate the pol gene (153). However. Nam. et al. found in
HTLV-1. that the Gag-Pro fusion protein occurs by ribosomal frameshifting (85).
Ribosomal frameshifting involves the slippage o f a tRNA one nucleotide in a forward or
reverse direction. As a result, the gag and gag-pol sequences are out o f frame with
respect to each other. In the HTLV family o f retroviruses. Bovine Leukemia Virus
(BLV). Mouse Mammary Tumor Virus (MMTV) and type D retroviruses. the,gt/gand
pol genes are separated by a pro ORF that overlaps both gag and pol (48. 8 1. 84. 98. 102.
108 117 127. The protease gene may be located at either the 3'end o f gag or the 5' end o f
pol i.e. Human Immunodeficiency Virus 1 (HIV-1) and Rous Sarcoma Virus (RSV)
(115. Thus. HTLV-1 utilizes a slight variant o f the frameshift mechanism to form their Pol
proteins. Two successive frameshifts must occur: (1) moving from the gag reading frame
into a short intermediate gene encoding the protease, and (2) moving from that reading
frame into the pol frame (Fig. 2). These frameshifts occur by a slippage o f asparagine
tRNA Oin the - I direction (83-84).

PROTEOLYTIC PROCESSING
After the HTLV-1 tusion proteins are translated, they are proteolytically processed
by the retroviral protease to produce the Gag. Pro and Pol proteins. The viral protease is
encoded in a separate reading frame overlapping the gag/pol coding sequences (23. 32)
(Fig. 2). Thus, the protease must, itself, be excised from a precursor protein. The
protease may autoprocess from within its precursor protein by cis catalysis.
Alternatively, the protease may be cleaved by trans catalysis through the actions o f a
neighboring Gag-Pol precursor (23).
Through site-directed mutagenesis studies, Nam et al. (1988) determined that the
catalytic center o f the HTLV-1 protease, consisting o f one o f the two conserved regions
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common to retroviral proteases, was identical to that o f an aspartyl protease (85). Other
reports confirm that mutations in Asp123 abolish protease activity (58. 82). Retroviral
aspartic proteases have a optimal pH range o f 4-6 while eukaryotic aspartic proteases
have an optimal activity range o f pH = 2-4. The difference in optimal activity range has
been attributed to the lack o f hydrogen bonding between Asp and Thr or Ser in eukaryotic
proteases. In retroviral proteases, the corresponding Thr or Ser is replaced by Ala. No
corresponding hydrogen bonding can occur: thus, the active Asp becomes less acidic, and
the pH optimum increases (33).
The mechanism by which the HTLV-1 protease cleaves its substrate is modeled
after that o f the HIV-1 protease since they are both aspartic proteases (46-47. 54) (Fig. 3).
The aspartic residues in the active site o f each monomer share a proton. The lytic water
molecule forms hydrogen bonds to the charged carboxylate. The Cp-C, bond o f A sp125
rotates to allow its proton to hydrogen bond to the carbonyl oxygen o f the substrate. The
Asp25 becomes more basic than Asp123 due to the loss o f the shared proton. The proton
from the lytic water can be abstracted to the carbonyl oxygen, forming a protonated
amide species. EA'H. The carbonyl carbon o f EA'H becomes an electrophilic substrate
for the water molecule. The amide hydrate intermediate. EXH. is then formed. Two
proton transfers lead to the tetrahedral intermediate EX'H. Finally the peptide bond is
broken and the fragments are created. The enzyme is then released in free form and may
process more substrate.

HTLV-1 REVERSE TRANSCRIPTASE
While a considerable amount o f information is known about the structure o f the
protease and gag proteins, not much is known about the structure and proteolytic
processing o f the reverse transcriptase o f HTLV-1 RT. Therefore, to further our
knowledge of molecular events during retroviral DNA synthesis, it is essential to
understand the architecture and functional organization o f the reverse transcriptase
molecule. Information about HTLV-1 RT. would allow for better understanding o f the
biology o f these viruses.
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FIG. 3. Proteolytic mechanism for the hydrolysis o f the Pro-Pol protein. The aspartic
residues o f the tree enzyme (EH), share a proton. After attack o f the substrate (EAH), a
protonated amide species is formed (EA 'H ). The carbonyl carbon o f EA 'H is attacked by
water to form the amide hydrate intermediate. EXH. After two proton transfers, a
tetrahedral intermediate is formed (EX’H). Finally the peptide bond is broken and the
products are free to dissociate. The enzyme can then trap another water molecule.
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The reverse transcriptase (deoxynucleoside triphosphate, DNA deoxynucleotidyl
transferase, RNA-directed E.C. 2.7.7.49) o f all retroviruses is encoded by the pol gene and
synthesized by the translation o f a full length viral mRNA, identical in structure to the
genomic RNA packaged into virions. It is never expressed as a separate protein, but rather
translated as part o f a large Gag-Pro-Pol protein (polyprotein precursor) (65). The reverse
transcriptase exhibits three enzymatic activities: RNA-dependent DNA polymerase.
Ribonuclease H (RNaseH) and DNA-dependent DNA polymerase (54). All o f these
enzymatic activities are essential for transcribing the single-stranded genomic RNA found
in the virions into the double-stranded linear DNA that is the precursor to the integrated
provirus.
The process o f reverse transcription is depicted in Fig. 4. As in the case o f all
DNA polymerases. RT needs a primer carrying a free 3'-OF! group to initiate DNA
synthesis. Retroviruses use host-encoded tRNAs as primers (64. 67. 72. 75). The tRNA
anneals to the primer-binding site (PBS) located near the 5' end o f the viral plus-strand
RNA. The RT recognizes the tRNA/RNA complex and initiates reverse transcription of
the minus-strand DNA by extending the 3' end o f the primer. The recessed template
strand guides DNA synthesis (6. 50). In copying the U5 and R regions o f the genome,
the RT forms a strong stop cDNA. Coupled with the synthesis o f DNA is the degradation
o f the RNA strand o f the newly formed RNADNA hybrid by the RNaseH (25. 34. 114).
The strong stop DNA is transferred to the 3'end o f genomic RNA in order to
continue synthesis o f the minus-strand DNA. This first strand transfer is facilitated b\ a
complementary R region at the 3'end o f the viral RNA. The two complementary R
sequences allow hybridization o f minus-strand DNA with plus-strand RNA, permitting
DNA synthesis to resume. As previously, the RNaseH activity o f the RT degrades the
RNA template. Synthesis of minus-strand DNA also entails the creation o f purine rich
fragments that function as RNA primers for plus-strand DNA synthesis (13-14. 45. 56,
146). Thus, the minus strand U3-R-U5 still attached to the tRNA primer is copied to
form the plus-strong-stop DNA. As plus-strand DNA synthesis proceeds to the PBS, the
original primer tRNA is degraded by the RNaseH activity.
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FIG. 4. Retroviral reverse transcription. The reverse transcriptase produces a double
stranded DNA from a single-stranded RNA through a sequence o f steps involving two
stand transfer events. The resulting linearized DNA is called the proviral DNA and is
inserted into the host to form the provirus.
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Once the primer tRNA is released, the second strand transfer occurs. The PBS on
the plus-strong-stop DNA anneals to the complementary PBS on the 3' elongated minus
strand and ligation o f the circular intermediate produces a linear duplex with LTRs (54).
The LTRs are duplicate R. U5. and U3 sequences. Thus, the proviral DNA differs in
length compared to the original RNA genome whose LTR contain the R region and either
the U5 or U3 region, respectively. The proviral DNA is then integrated into the host to
form the provirus.
There are common biochemical properties of RT from different viruses, i.e. primertemplates and divalent cations. But. they also differ in molecular weight, in subunit
composition, function, and in their sensitivities to polymerase inhibitors. For example.
Murine Leukemia Virus RT is a single polypeptide chain that carries both reverse
transcriptase activity and RNaseH activity, while some retroviral reverse transcriptases
may be divided into two domains each exhibiting only one enzymatic activity. Avian
Myoblastosis Virus RT consists o f two subunits, alpha and beta. The larger subunit
carries the integrase function as well as the RNaseH and polymerase activities: the
smaller subunit carries polymerase and RNaseH activities (43, 125)

PREVIOUS RESEARCH
To date, not much is known about the reverse transcriptase o f HTLV-1.
Retroviral polymerases from different taxonomic classes show a preference for certain
synthetic template-primer combinations. Transcription also requires a divalent cation:
Mg2' or Mn: \ The majority o f retroviruses preferentially use Mg2' (65). In the first
reported information about HTLV-l RT. Rho et al.( 101) characterized the enzyme from
the virion. They found that this RT has an apparent MW o f 95.000. that Mg 2' is the
preferred divalent cation, and that polv(rC)«oligo(dG) is the preferred primer-template in
vitro. However, this group could not obtain much protein from their isolation method from
human cell infected lines. Further characterization o f the enzyme was not performed.
Subsequently. Hoffman et al. found that HTLV-I RT isolated from infected MT-2 cells
preferred Mn2* with both a po!y(rA)«oligo(dT) and poIy(rCm)« oligo(dG) primer
template, but Mg2* for a poly(rC)«oligo(dG) template primer (43). Most recently. Owen
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et al. expressed a recombinant HTLV-1 protein with reverse transcriptase activity. This
protein has an approximate MW o f 60,000-65.000, and prefers a Mg2' divalent cation on
a poly(rC)«oligo(dG) template (91).
The exact sites o f protease cleavage have been identified for a number o f viral
polyproteins by comparing the amino acid sequences o f the precursors, deduced from the
proviral DNA sequence. The N- and C-terminal amino acid sequences o f mature viral
proteins were determined by direct protein sequencing techniques. However, the actual
identity of the authentic N-terminus from virion-produced HTLV-1 RT has not been
identified from mature, processed protein.
Two very recent reports have been published on the expression o f the RT of
HTLV-I. In the first. Owen et al. expressed an enzymatically active HTLV-1 RT in
bacteria. They began their construct such that translation was initiated at Pro” , which is
located within the proposed pro-pol frameshift site (91). This group made no effort to
determine the correct N-terminal sequence (proteolytic processing). In the second report.
Trentin et al. hypothesized that the N-terminus o f the RT should immediately follow the
known C-terminus o f the protease. By using sequence alignments with other retroviral
sequences, they demonstrated that there was no known function for the sequence encoded
between the C-terminus o f the protease and Pro ”. Based on the similarity o f the
sequence of other RTs. the protein coding sequence should begin at Pro ”. The protein
resulting from their construct also had RT activity (131). However, they used an in vitro
transcription/translation system which could have an impact on the overall folding and
potential subunit structure. In addition, Trentin et al. assumed that the HTLV-1 RT
sequence is similar to that of the RT o f avian sarcoma virus (ASV). Based on this, they
deduced an oligomeric structure o f the RT and claimed to have obtained an exclusive
enzymatically active RT form, the a ,/p tetramer. This is a molecular arrangement never
encountered before in retroviral RTs (16. 41. 125). Taken together, there are
discrepancies between the two published reports on recombinant HTLV-1 RT.
Furthermore, Perach et al. (92) found that the amino acid sequence requirements and
molecular arrangements o f the recombinant BLV RT are substantially different from
those o f both H TLV-l RT studies. These unique differences among relatively close RTs
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should be helpful to future studies designed to study structure-function relationships o f
these RTs.
HTLV-1 viruses show very limited sequence variation in comparison to a much
greater variation seen among different isolates of each lentivirus in the HIV/SI V family (28.
30. 57. 71. 77). Ratner et al. reports a l.2%-3.3% nucleotide sequence difference among
HTLV-1 isolates (100). The identification o f possible regions o f functional importance can
be unequivocally determined by comparative sequence analysis because o f the genomic
stability o f HTLV-1 and minimal strain variation between isolates. As each of the
functional aspects becomes better understood, targets for antiviral intervention against
HTLV-1 associated diseases will emerge.

DEVELOPMENT OF THE RESEARCH METHODOLOGY
In light o f the facts presented, the ultimate goal o f this project is to characterize the
reverse transcriptase enzyme o f HTLV-1. Successful expression of this replication
enzyme would allow for a detailed biochemical characterization as well as a comparison
of structure-function relationships with reverse transcriptases from HIV and other
retroviruses. The expression system for the HTLV-1 RT was developed in 1995 by my
advisor. Dr. Laura Moen. The plasmid, pRCH (generously provided by Dr. Lee Ratner o f
Washington University), which contained the cDNA from a replication competent isolate
of HTLV-1. was used to create the desired protein expression system. The intact HTLV-I
pol gene was cloned using a pET vector for expression. The desired sequence was
amplified using PCR. To mimic the second frameshift in the pol ORF. an extra C was
inserted at the second frameshift site when the primers were made. Since the expression
vector used to insert our clone (pET 24) contained the Bam and EcoRl restriction sties, our
clone was made such that the clone had a Bam site at its N-terminus (Pro158). After the
expression vector is cut open with Bam and EcoRl restriction enzymes, the clone is ligated
in the opened vector. This coding sequence was cloned in frame with the 10 amino acid T7
tag sequence in pET24b to facilitate expression and detection on a Western.
Originally, two clones were created because the structure o f the RT and the cleavage
sites in pol were unknown. The p o l ORF o f HIV-I also encodes for reverse transcriptase.
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FIG . 5. Strategy for the amplification o f the intact HTLV-l RT coding sequence. (A)
Expression system for reverse transcriptase with RNaseH; Mr = 65,000. (B) Expression
system for reverse transcriptase with integrase: Mr = 99,000.
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RNaseH and integrase (endonuclease) domains. This Pol polypeptide is further processed
to produce a mature reverse transcriptase and a separate mature endonuclease protein (23).
The HTLV-I RT protein may act in a similar fashion. On the other hand, the HTLV-I RT
protein may have similar functions to other reverse transcriptases such as Rous Sarcoma
Virus RT which possesses both a reverse transcriptase and endonuclease domain (23).
Given this background information, the clones shown in Fig. 5 were produced: (1) The
short clone was constructed with a stop codon at amino acid 591 which terminated the
coding sequence at the end o f the RNaseH domain. (2) The large clone included the
integrase domain and terminated at the native pol stop codon.
Since the sites o f protease cleavage in the pol region have not been identified
other than those required for the production o f mature protease, the clones were created
with a putative N-terminus. The actual identity o f the authentic N-terminus from virionproduced HTLV-1 RT has not been identified and confirmed. Dr. Laura Moen and her
post-doctoral associate, Imogene Richardson, carried out a sequence alignment with
several reverse transcriptases which included that from Bovine Leukemia Virus, the
closest characterized relative to HTLV-1. A portion o f that alignment, shown in Fig. 6.
suggests that the N-terminus of HTLV-1 RT is likely to start where the viral protease Cterminus ends. Therefore, both of the clones were constructed to contain this sequence at
the N-terminal region.
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FIG. 6. Sequence to determine the N-terminus o f HTLV-l RT. The amino acid
sequences at the N-terminal regions o f H IV -1 and BLV RTs are aligned with the Nterminal regions for HTLV-1 and HTLV-2. The last boxed region contains the sequences
surrounding the frameshift in the pol reading frame (between L and N o f HTLV-1 and
HTLV-2).
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RESEARCH OBJECTIVES
As previously stated, Owen et al. reported that a smaller recombinant protein from
an MT-2 HTLV-1 cDNA exhibits RT activity (91). The coding sequence o f this protein
begins after the ribosomal frameshift and ends at the end o f the RNaseH domain. Efforts
to produce the short clone which would be analogous to that reported by Owen et al. did
not succeed; the smaller protein was rapidly degraded as it was synthesized. The
instability o f this protein that was observed may be due to as yet undetermined protein
folding differences between the two proteins and perhaps by the different expression
systems employed. The results o f expression o f the longer clone which included the
integrase domain, however, showed significantly higher levels o f expression on Western
blots. It is with this longer clone that a purification scheme was developed. Further
investigation was necessary to clarify the reasons for folding differences and to
unequivocally identify the mature form o f the authentic HTLV-1 RT. The specific aims
o f this research are to:
I. Purify' a recombinant HTLV-I RT
With the availability of primary sequences for RNA-dependent DNA polymerases, it has
become possible to compare and delineate some of the highly conserved regions found in
polymerases from diverse origins. Sequence alignments among these polymerases have
revealed four conserved motifs (94). Genetic studies o f these conserved regions have
demonstrated a critical role for these residues in the catalytic function o f these
polymerases (9. 31. 62. 97. 109). For example, the invariant DD motif in m otif 3 o f these
polymerases is thought to be at the polymerase active site. For related polymerases,
published procedures can be used as a starting point and modifications made later to
improve the specific activity, purity, and recovery o f the enzyme. Since the location o f
the active site o f the HTLV-1 RT is not known and thus, the amino acids involved in
catalysis, other retroviral reverse transcriptase purification schemes were used as a basis.
Consequently, several different ligands were analyzed.
Several sensitive methods exist for protein characterization. These
chromatographic methods include ion exchange. DNA affinity, metal chelate affinity,
hydrophobic interaction, precipitation, ammonium sulfate, polyethyleneimine and high
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performance liquid chromatography (HPLC). All o f these methods were used to
empirically determine the optimal conditions for adsorption o f the RT. Analysis o f purity
o f the final product was assessed using SDS-PAGE analysis, gradient gels, gel filtration.
Western Blotting, and measurement o f reverse transcriptase activity. Further
characterization involved template specificity and stability studies.
2. Confirm the proteolytic processing site o f the N-terminus o f HTL V-l RT
Results from the stability studies were in agreement with others in that the activity o f the
enzyme is consistently low. An earlier report by Hizi. et al. demonstrated that the first 20
amino terminal acids o f HIV-1 RT are required for an active enzyme (42). The low
activity observed in this study and/or others may be due to an incorrect coding sequence
for the HTLV-I RT. Moreover, the N-terminal proteolytic cleavage site o f HTLV-l RT
has not been determined. Therefore, to confirm the HTLV-1 RT purified in this project
contains the authentic N-terminus. clones coding for the expression o f a protein fragment
spanning the pro-pol junction were constructed. The clone was purified using methods
described in objective 1 and cleaved using recombinant HTLV-1 protease.
The peptide fragments were analyzed by LC-MS and MS/MS at the
Biomoiecular Research Facility at the University o f Virginia by Dr. Nicholas Sherman.
In recent years, mass spectrometric methods have emerged as powerful tools for protein
characterization (124). Protein amino acid sequences can be determined by tandem mass
spectrometry using a triple-quadrupole mass spectrometer. In this process, protonated
peptide ions are selected with the first mass spectrometer and are transmitted to a
collision cell. Low energy collision with neutral inert gases results in fragment ions that
are then detected in a second mass spectrometer. The fragmentation patterns o f peptides
obtained are indicative o f their amino acid sequences and thereby allow for the
determination o f peptide sequences as well as determination o f any posttranslational
modifications occurring within the protein. Analysis o f the Pro-Pol protein fragments by
LC-MS and MS/MS was used to determine the location o f the cleavage site which is
presumably used to generate mature reverse transcriptase from Gag-Pro-Pol polyproteins
expressed in vivo in HTLV-1. Since the sequence o f the Pro-Pol protein is already
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known, confirmation o f the peptide fragments can be rapidly performed by mass
measurement.

PROJECT SUMMARY
The retroviral replicative cycle has been intensively studied in order to identify
possible targets for designing inhibitors, which may become powerful therapeutic agents.
While HTLV-1 is not as prevalent as other retroviruses i.e. HIV. coinfection with HIV may
have a serious impact. In order to deal with the consequences o f a widespread infection and
disease before an epidemic occurs, we can study the replicative mechanisms o f HTLV.
The reverse transcriptase plays a crucial role in the early stages o f viral replication.
To understand the architecture and functional organization o f the reverse transcriptase
molecule, a recombinant enzyme expressed in E.culi will be purified. By using a
recombinant source o f HTLV-l RT. some o f the biochemical properties o f HTLV-l RT can
be determined. Confirmation of the protein as authentic will provide a basis for further
studies on the structural aspects of protein nucleic acid interaction.
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CHAPTER II
MATERIALS AND METHODS
PREPARATION OF MEDIA
To optimize the growth o f the two different types o f E. coli strains, nutrient rich
media was prepared. Luria Broth (LB: Difco. Detroit. MI) was prepared by dissolving 25
g o f LB powder in 1 L MiiliQ water to a final concentration o f 10 g bacto-tryptone, 5 g
bacto-yeast extract and 10 g NaCl per liter o f LB. The solution was autoelaved
(Sterilmatic. Market Forge Co.. Everitt. MA) at 240°C for 20 minutes.
1.4 g of agar (Fisher. Indianapolis. IN )/100 mL LB was autoelaved to create solid
media for pouring plates. After cooling to 50°C. the solution was poured into sterile petri
dishes (Fisher)) and allowed to polymerize at room temperature. If antibiotics were
required in the media to enhance the growth o f plasmid DNA and/or E. coli cultures, they
were added to the media upon cooling to 50°C.

PREPARATION OF COMPETENT E. coli
The preparation o f BL2l(DE3)pLysS (Novagen. Madison, WI) and W3110(DE3)
competent E. coli was performed using the CaCL method outlined in Current Protocols in
Molecular Biology (16). The BL21(DE3)pLysS host strain carries a plasmid with the T7
Ivsozyme gene which confers resistance to chloramphenicol. In which case. LB media
was supplemented with chloramphenicol to a final concentration o f 34|ug/mL in all steps
o f this procedure. Unless otherwise stated, any protocol described hereafter in which the
BL21(DE3)pLysS host E.coli strain is grown, utilizes LB supplemented with 34 fig/mL
chloramphenicol as its growth media. The 34 mg/mL chloramphenicol stock solution
was made by dissolving 34 mg o f chloramphenicol (Fisher) in I mL 100% ethyl alcohol
(AAPER Alcohol and Chemical Co., Shelbyville, K.Y).
An LB plate was streaked with the E. coli strain o f choice using a sterile
inoculation loop. The plate was incubated in a 37°C incubator (Fisher) for approximately
14-16 hours. The following day, a single colony was used to inoculate 3 mL o f LB
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media. The single colony was grown overnight at 37°C while shaking at 250 rpm (Orbit
Environ Shaker. Lab-Line Instruments. Inc.). On the third day. a 1 mL aliquot o f the
overnight culture was inoculated into 100 mL sterile LB media in a 500 mL flask. The
culture was grown at 37°C. while shaking at 250 rpm. to an O.D.*,,,, = 0.375. The culture
was divided into 50 mL aliquots by pouring the culture into two pre-chilled. sterile,
polypropylene centrifuge tubes. After leaving the tubes on ice for 10 minutes, the
suspension was centrifuged for 7 minutes at 3000 rpm (Beckman GPR. Fullerton. CA).
At all centrifugation steps in this protocol, the tubes were allowed to decelerate without
braking. The supernatant was discarded and each pellet was resuspended in 10 mL icecold, filter sterilized CaCL (60 mM CaCL. 15% glycerol. 10 mM PIPES. pH 7). The
suspension was centrifuged for 5 minutes at 2500 rpm. The supernatant was again
discarded and each of the pellets resuspended in 10 mL ice-cold CaCL. The suspended
bacteria were kept on ice for 30 minutes and were centrifuged again for 5 minutes at 2500
rpm. In the last step, the supernatant was discarded and each of the pellets was
resuspended in 2 mL ice-cold CaCL. These competent bacteria were stored in 16-250 p.L
aliquots in 1.5 mL sterile, polypropylene tubes (Fisher) at -70°C.

EXPRESSION SYSTEMS
A plasmid pRCH (generously donated by Dr. Lee Ratner of Washington
University) containing the entire genome from an HTLV-l strain was used to amplify the
entire coding region for the polymerase and the protease. The cDNAs were prepared by
Dr. Laura Moen and Barbara Conyers using a Perfect Prepi£> (5 Prime—> 3 Prime.
Boulder, CO) DNA preparation kit. All three expression systems were developed using
pET vectors (Novagen). These cloning vectors contain specific antibiotic resistant genes
to allow for growth selection on media plates. Both pET24 and pET29 carry the
kanamvcin resistant gene. pET19 carries the ampicillin resistant gene.
The RT coding sequence was cloned in-frame with the 10-amino acid T7 tag
sequence in pET24b which facilitated the detection o f the expression product by Western
blot. The protease coding sequence was cloned in-frame with an N-terminal
polyhistidine tag (His-tag) in pET19, which facilitates purification with an immobilized
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nickel affinity column. A Pro-Pol protein clone, which spans a region where the protease
is known to terminate and continues past the pro-pol frameshift. was cloned in-frame
with the N-terminal 16 amino acid S-tag in pET29 which facilitates detection o f the
expression product by Western blot. The coding sequence also contained a C-terminal
His-tag.
Before transformation in E. coli. the plasmid DNAs were digested with the
appropriate restriction enzymes and analyzed by agarose gel electrophoresis to confirm
that the correct plasmids were obtained. Because the DNA is cut at specific sites, a
distinct pattern o f bands for each cDNA is apparent with ethidium bromide staining. The
plasmid DNAs. pET24ab3#12 (RT), IK 19 (protease), and peptide (Pro-Pol protein) were
stored as glycerol stocks in either XL-Blue or AG1 cells.

ISOLATION OF PLASMID DNA
A BIGGER prepoD Plasmid DNA Preparation Kit (5 Prime -> 3 Prime. Inc.) was
used to prepare plasmid DNAs for the HTLV-1 RT. the HTLV-1 protease and the Pro-Pol
protein expression constructs. Unless otherwise stated, all steps in the procedure were
performed at room temperature. The DNA stock was streaked on an LB/agar plate
supplemented with appropriate antibiotic and grown for 14-16 hours in a 37°C incubator.
25 mg/mL stock kanamvcin was made by dissolving 25 mg o f kanamycin (Sigma. St.
Louis. MO) in I mL MilliQ water. If supplemented with kanamycin, the 25 mg/mL stock
was added to final concentration o f 50 pg/mL in media. To supplement media requiring
ampicillin, the appropriate number o f 2.5 mg ampicillin tablets (Stratagene. La Jolla, CA)
was dissolved directly in media to give a final concentration o f 100 pg/mL ampicillin.
The following day, the plate was stored at 4°C until late afternoon, at which time,
a single colony was inoculated in 500 mL LB with the appropriate antibiotic and
incubated overnight at 37°C with shaking at 250 rpm. The bacteria was pelleted in 2-250
mL centrifuge bottles by centrifugation (Beckman Model J 2-21) at 10,000 x g for 3
minutes. The supernatant was discarded and the plasmid DNA was isolated from the
pellet by following the manufacturer’s instructions. In brief, the pellet was treated with a
buffered RNase A solution, lysed with alkaline lysis solution, and neutralized with
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potassium acetate solution. Unless otherwise stated, all solutions were provided in the
preparatory kit. The plasmid DNA in the neutralized bacterial lysate was then bound to a
DNA binding matrix suspension. The resulting DNA binding matrix/plasmid DNA
solution was washed with several aliquots o f buffered salt solution followed by elution o f
the purified plasmid DNA with heated TE solution. pH 8.0. The eluted purified plasmid
DNA was then precipitated by the addition o f 5 M NaCl and 95% ethanol. The solution
was mixed and the plasmid DNA was pelleted by centrifugation at 16.000 x g for 5
minutes. After carefully removing the supernatant, the plasmid DNA pellet was washed
twice with 70% ethanol and air dried overnight to remove the ethanol. The next day. the
pellet was resuspended in 100 pi sterile water to rinse the side of the tube. The purified
plasmid DNA was transferred to a 0.5 mL sterile, siliconized, eppendorf tube (Fisher) and
stored at -20°C.

QUANTITATION OF DNA
An aliquot o f the DNA sample was diluted either 1:50 or 1:100 with sterile water.
The amount o f DNA in the samples was determined spectrophotometrically using the
Cary UV/VIS Spectrophotometer (Varian Model 3-Bio. Palo Alto. CA). The absorbance
of the dilute sample was read at 260 nm and 280 nm. The reading at 260 nm allows for
the calculation o f the concentration o f nucleic acid in the sample. An O.D. = 1
corresponds to approximately 50 pg/mL for double-stranded DNA. Thus, the following
equation was developed to calculate the concentration o f nucleic acid in the sample:
A:fi0 x dilution factor x 50 pg/mL = X pg/mL DNA
The ratio between the readings at 260 nm to 280 nm provides an estimate for the purity o f
the nucleic acid. If this ratio was near 1.8. the original DNA sample was stored at -20°C
and used for the transformation o f plasmid DNA in E. coli.

TRANSFORMATION OF COMPETENT E. coli WITH PLASMID DNA
Because the competent E. coli were stored in CaCL. they were exposed to
calcium ions which allow the cells to take up DNA. The bacterial cell membrane is
permeable to chloride ions, but is non-permeable to calcium ions. As the chloride ions
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enter the cell, water molecules accompany the charged particle. This influx o f water
causes the cells to swell and is necessary for the uptake o f DNA. The exact
mechanism o f this uptake is unknown. It is known, however, that the calcium chloride
treatment m ust be followed by heat.
A 250 pL aliquot of competent E. coli was allowed to thaw on ice. 100 p.L o f E.
coli was transferred to a 14 mL sterile, round bottom, polypropylene tube (Fisher) which
was also kept on ice. The bacteria were incubated with 1.7 pi o f a 1:10 dilution o f Pmercaptoethanol (Fisher) for 10 minutes with gentle swirling every two minutes.
Approximately 1 pg of DNA (~ 1-2 pL) was added to the cells and the solution was
allowed to incubate on ice for 30 minutes.
When E. coli are subjected to 42°C heat, heat shock genes are expressed which
aid the bacteria in surviving at such temperatures. The heat shock step is necessary for
the uptake o f DNA. At temperatures > 42°C. the bacteria's ability to uptake DNA
becomes reduced, and at extreme temperatures the bacteria will die. Therefore, in the
next step the tube was placed in a 42°C water bath for 45 seconds. The tube was then
quickly placed in ice for 2 minutes. 900 pL o f sterile SOC media (0.5% yeast extract.
2% tryptone. 10 mM NaCl. 2.5 mM K.C1. 10 mM MgCL, 10 mM MgSO^and 20 mM
glucose) was added to the tube and the tube was incubated for I hour at 37°C with
shaking at 250 rpm. All of the bacteria were pelleted by centrifugation at 1000 rpm for
10 minutes. The supernatant was gently discarded and the remaining slurry o f pelleted E.
coli DNA was plated on an LB/antibiotic plate using a spreader to evenly distribute the
bacteria. The spreader was initially sterilized by dipping the spreader in ethanol, passing
the spreader through a gas flame to ignite the ethanol, and allowing the flame to bum out.
The spreader was cooled by touching the surface o f the LB plate. The plate was
incubated overnight in a 37°C incubator.
The next morning the plate containing several isolated colonies was stored at 4°C
until ready to be cultured. Ideally, the plates should not be stored for more than one
week.
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PREPARATION OF BACTERIAL PELLETS
Reverse Transcriptase
Ten flasks containing 500 mL Luria Broth, 50 pg/mL kanamycin were inoculated with a
single colony each o f W3110(DE3) containing the pET24ab3#12 expression plasmid.
The flasks were incubated with shaking at 37°C until the culture reached an O.D.gQO ° f
0.6-0.9. at which point 800 mM isopropyl-P-D-thiogalactoside (IPTG; Promega.
Madison. WI) was added to a final concentration o f 1 mM. 2 hours after the addition of
IPTG. cultures were pelleted by centrifugation at 10.000 RPM for 20 minutes at 4°C.
The cultures were harvested in 250 mL bottles. The supernatant was discarded with care
so as not to disturb the bacterial pellet. Two 250 mL pellets were scraped from the bottle
and combined into one 500 mL pellet on a tared piece o f aluminum foil so that the
pellet's wet weight could be measured. Finally, the pellet was wrapped in the aluminum
foil. labeled with its wet weight and stored at -70°C. All 10-500 mL pellets were
harvested in the same manner.
Protease
A flask containing 100 mL Luria Broth. 100 pg/mL ampicillin and 34 |ig/mL
chloramphenicol was inoculated with a single colony o f BL2lpLysS(DE3) containing
the protease expression plasmid. The flask was incubated with shaking at 37°C until the
culture reached an O.D.600 o f 0.6-0.9. at which point 800 mM IPTG was added to a final
concentration o f I mM. 2 hours after the addition o f IPTG, cultures were pelleted by
centrifugation at 10.000 RPM for 20 minutes at 4°C. The supernatant was discarded with
care so as not to disturb the bacterial pellet. The 100 mL pellet was scraped from the
bottle and transferred to a tared 2.0 mL round bottom, self-standing cryovial (Fisher).
The cryovial was labeled with the pellet wet weight, frozen in liquid N2 and stored at 70°C.
Pro-Pol protein
Two flasks containing 500 mL Luria Broth, 50 pg/mL kanamycin and 34 pg/mL
chloramphenicol were inoculated with a single colony each o f BL21pLysS(DE3)
containing the Pro-Pol expression plasmid. The flasks were incubated with shaking at
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37°C until the culture reached an O.D.^OO o f 10-1.2, at which point 800 mM IPTG was
added to a final concentration o f I mM. 45 minutes after the addition o f IPTG. cultures
were pelleted by centrifugation at 10.000 RPM for 20 minutes at 4°C. The cultures were
harvested in 250 mL bottles. The supernatant was discarded with care so as not to disturb
the bacterial cell pellet. Two 250 mL pellets were scraped from the bottle and combined
into one 500 mL pellet on a tared piece o f aluminum foil so that the pellet’s wet weight
could be measured. Finally, the pellet was wrapped in the aluminum foil, labeled with its
wet weight, frozen in liquid N : and stored at -70°C. Both 500 mL pellets were harvested
in the same manner.

PREPARATION OF CHROMATOGRAPHIC RESINS
Phosphocellulose (P -l 1)
To determine the amount of phosphocellulose cation exchanger (Whatman. Maidstone,
England) resin to pre-cycle, the approximate bed volume was approximated using the
standard formula for the volume o f a cylinder:
volume = 7t x r x h

r = radius o f the column
h = height of the column

With a column height = 20 cm and column i.d. = 5 cm. the bed volume would be 392 mL.
The amount o f dry phophocelluiose will swell to double its volume in MilliQ water.
Therefore, approximately 200 mL o f dry phosphocellulose resin was placed in a 1 L
graduated beaker and allowed to swell in 300 mL MilliQ water. After the resin had
settled, the water was carefully decanted. Two-500 mL washes o f 1 N NaOH (Fisher)
were added to the beaker to start the basic pre-cycling. The resin was allowed to settle
for 5 minutes between washes. The 1 N NaOH was decanted into a waste beaker. The
resin was washed with 250 mL aliquots o f MilliQ water until a pH < 10 was reached.
Each time, the resin was allowed to settle for 5 minutes before decanting.
Acid pre-treatment followed by adding two 500 mL volumes o f IN HC1 (Fisher)
to the resin. The resin was allowed to settle for 5 minutes and the acid was decanted.
The resin was washed with 250 ml aliquots o f MilliQ water until a pH > 4 was reached.
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The resin was washed once more with 500 mL MilliQ water. The final phophocellulose
slurry was incubated with I L o f 10X Reverse Transcriptase Buffer (RTB: 500 mM K.CI
500 mM Tris, pH 7.5. 25 mM EDTA, 1% Triton X-100) and stored in a 1 L bottle at 4°C.
All reagents in the buffer were purchased from Fisher.
After the phosphocellulose slurry had equilibrated in the 10X RTB for at least two
days, the buffer was decanted, and the bottle o f phosphocellulose slurry was warmed in a
30°C water bath for 1 hour. Approximately 500 mL o f RTB-50 (IX RTB; 50 mM K.C1.
50 mM Tris. pH 7.5. 2.5 mM EDTA. 0.1% Triton X-100) was added to the media slurry.
Meanwhile. 500 mL RTB-50 was poured into an empty column (BioRad. Hercules. CA)
to wash the column and to determine if the stopcock was functioning properly. The
column outlet was opened to allow 5% o f the buffer to flow out and to remove air from
the space beneath the column bed support and the outlet tubing.
After 5% o f the buffer had passed through the column, the column was packed
with the phosphocellulose slurry. The 1 L bottle o f slurry was swirled several times and
the slurry was added to the column in one single operation. The resin was allowed to
settle by gravity with the column outlet closed. After the bed was formed, the outlet was
opened and the excess liquid on the top o f the column was allowed to enter the bed. until
approximately 1 cm remained above the bed surface. The column was equilibrated in
RTB-50 by running the buffer through the column until the pH o f the eluate was 7.0.
Sepharo.se CL-6B
The gel filtration media, sepharose CL-6B (Pharmacia Biotech. Uppsala, Sweden), was
resuspended by shaking the bottle. 700 mL o f the resuspended gel was transferred to a 1
L flask. The gel was allowed to settle, the excess liquid was decanted and the gel was
resuspended in 500 mL RTB-50. The excess buffer was decanted after settling, and 300
mL o f RTB-50 was added to the gel to make a slurry The slurry was then de-gassed by
bubbling in N-, for I hour.
Meanwhile. I L o f RTB-50 was poured into the outlet tubing o f an empty column
(XK 50/60, Pharmacia), until it passed through the bed support net. The column outlet
was closed when the dead space under the net was properly filled. The entire slurry was
poured into the column in a single operation using a reservoir. The outlet valve was
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opened and the packing o f the column was initiated by gravity flow. When all the gel had
sedimented to the bottom, the reservoir was removed and the adapter was inserted. The
flow adapter was adjusted to the surface o f the gel bed when the gel was thoroughly
packed into the column. The column was equilibrated with 2 L o f RTB-50 by running
the buffer through the column overnight in a 4°C cold box. The column remained at 4°C
for the entire standardization and purification procedures.
Gel filtration molecular weight markers (Sigma) ranging from 12.000 -200.000 Da
were used to calibrate the column. The procedure for determining molecular weight
outlined in the Sigma bulletin is a modification o f the methods of Whitaker (135) and
Andrews (2). Molecular weight determinations o f unknown proteins are made by
comparing the ratio of V /V u for the protein in question to the V /V 0 o f protein standards
of known molecular weight (Ve = elution volumetV, = void volume). A calibration
curve can then be prepared by plotting the logarithms o f the known molecular weights o f
protein standards versus their respective V yV , values. The apparent molecular weight o f
the HTLV-1 protein was calculated from the standard curve (Appendix A) determined by
calibration of the column with molecular weight standards: blue dextran (Mr =
2.000.000). carbonic anyhydrase (M r = 29.000). alcohol dehydrogenase (M, = 150.000).
P-amylase (Mr = 200.000), and cytochrome C (Mr = 12.400).
Table I shows the molecular weights and concentration o f markers applied to the
column. The final concentrations o f each marker, suggested by the manufacturer, would
give an Also o f approximately 1.0 in the peak fraction. The void volume was determined
based on the volume of effluent required for the elution o f the large molecule, blue
dextran (Mr= 2.000.000). 2 mL o f 2 mg/mL blue dextran was carefully applied to the
column. The column was connected to an Econo Pump (Model EP-l.BioRad). an Econo
UV monitor (Model EM-1. BioRad). an Econo chart recorder (Model 1325. BioRad). and
a fraction collector (Model 2110. BioRad). To minimize mixing, all pieces o f the
apparatus connected to the outlet were placed as close as possible to the outlet tubing.
RTB-50 was pumped through the column at a rate o f 0.5 mL/min to elute the blue
dextran. The chart recorder, set at 200 mV, I cm/hr, recorded signals from the UV
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TABLE I
Preparation o f Protein Standards for Sepharose CL-6B Calibration Curve
Concentration (mg/mL)'1

Protein Standard

Molecular Weight (Daltons)

blue dextran

2.000.000

P-amylase

200.000

4

alcohol dehydrogenase

150.000

5

albumin

66.000

10

carbonic anhydrase

29.000

j

cytochrome C

12.400

2

JIndividual protein standards were dissolved in RTB-50 containing 5 % glycerol.
2 mL o f individual samples containing the following concentrations, as mg solid per mL
o f buffer, should give an A:so = 1.0 in the peak fraction.
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monitor programmed to read absorbances at 280 nm. The traction collector was set at 8
mL/tube. This void volume was calculated using the following formula:
cm peak x hr/cm (chart speed) x 60 min/hr x 0.5mL/min (pump speed) = volume (mL)
migrated
To confirm the void volume, the absorbance of the tubes containing the peak fractions
and the tubes located before and after the peak were read again manually at 280 nm using
the department’s Cary UV/Vis Spectrophotometer.
Each of the protein standards was applied as described. The column was allowed
to equilibrate in 1 L of RTB-50 at 0.5 mL/min between each run. The elution volumes o f
the standards were denoted and the calibration curve (Appendix A) was graphed using
CA Cricket Graph III Software (Computer Associates).

PURIFICATION OF HTLV-1 REVERSE TRANSCRIPTASE
Unless otherwise indicated, all steps were carried out at 4°C. Each 500 mL bacterial
pellet was resuspended in 20 mL o f STET buffer (50 mM Tris: 8% sucrose: 50 mM
EDTA and 5% Triton X-100) supplemented with 10 mg/mL lysozyme and a protease
inhibitor cocktail (Boehringer Mannheim. Atlanta. GA) containing aprotinin. leupeptin.
pepstatin. phenylmethylsulfonylfluoride (PMSF). antipain, chymostatin, peflabloc and E64. Stock solutions were prepared according to Table II. The bacterial pellet in STET
solution was kept on ice for I hour. The thawed pellet was vortexed vigorously and DNA
was sheared with a sonic dismembrator (Fisher Sonic Dismembrator 60) using 4-15
second pulses. Finally, the suspension was cleared by centrifugation for 30 minutes at
12.000 RPM to remove insoluble debris. The supernatant from each 500 mL pellet was
combined to make the 200 mL crude lysate.
Phosphocellulose chromatography o f HTLV-l RT
The crude lysate was applied at a flow rate of 0.5 mL/min to a phosphocellulose column
(20 cm x 5.0 cm i.d.) equilibrated in RTB-50. The column was eluted with an 800 mL
linear gradient of 0.1 to 1 M K.C1 in RTB-50 supplemented with 10% glycerol (glycerol),
1 mM PMSF and 2 mM dithiothreitol (DTT, Fisher). Fractions o f 8 mL were collected
and assayed for reverse transcriptase activity as described later in this section.
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TABLE II
Preparation o f Protease Inhibitor Cocktail
Protease Inhibitor

Concentration o f
Stock Solution-1

Diluent Buffer

Concentration in
STET Buffer

antipain

50 pM

MilliQ water

0.1 pM

aprotinin

76 pM

MilliQ water

0.1 pM

ehvmostatin

500 pM

glacial acetic acid

1 pM

E-64

1mM

1:1
H20 /100 % ethanol

I pM

leupeptin

1mM

MilliQ water

1 pM

peflabloc

84 mM

MilliQ water

0.4 mM

pepstatin

700 pM

methanol

1 pM

PMSF

100 mM

100 % ethanol

1 mM

''All stock solutions were stored as 200-300 pL aliquots in 1.5 mL sterile, eppendorf
tubes at -20°C.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

34

Ammonium Sulfate Precipitation
The fractions containing the majority of enzyme activity were pooled in a 100 mL beaker,
which was then placed on a stir plate in the 4°C cold box. The pool was precipitated with
saturated ammonium sulfate (Fisher) to 65 % saturation (0.3432 g/mL; a saturated
solution = 4 M (NH4)2S 0 4 = 528 g/L = 0.528 g/mL). The solution was mixed with a
magnetic stir bar until all o f the ammonium sulfate was dissolved. The pool was
transferred to a centrifuge tube and centrifuged at 10.000 RPM for 20 minutes. The
supernatant was discarded and the pellet was resuspended in 1.5-2.0 mL. RTB-50. I’he
suspension was placed in 12.000-14.000 MW cut-off Spectra/Por® dialysis tubing
(Fisher) and dialyzed against 1 L RTB-50 for 4 hours. The buffer was changed at 2
hours. The sample was removed from the dialysis tubing and centrifuged again at 40.000
RPM for 20 minutes to remove cellular debris.
Sepharose CL-6B chromatography
The supernatant was loaded on a column (52 cm x 5 cm i.d.) o f Sepharose CL-6B.
equilibrated in RTB-50. The column was developed using the parameters predetermined
in the calibration procedure. The apparent molecular weight was computed from the
elution volume of the peak absorbance and the equation for the linear regression line o f
the standard curve was determined by calibration o f the column with molecular weight
standards: blue dextran (Mr = 2.000.000). carbonic anvhvdrase (Mr = 29.000). alcohol
dehydrogenase (Mr = 150.000), p-amylase (Mr = 200.000). and cytochrome C (Mr 12.400). The peak fractions were also assayed for reverse transcriptase activity as
described later in the next section.

REVERSE TRANSCRIPTASE ASSAYS
10 pL o f each fraction was pipetted into 40 jaL o f reaction cocktail (final
concentration: 50 mM Tris-HCl (pH 8.8). 80 mM KC1. 6 mM M gC h, 8 mM DTT.
0.05% Triton X-100. 80 mM dGTP or dTTP (Promega), 1 mM [3H]dGTP (30 Ci/mmol)
or [3H]dTTP (104 Ci/mmol)(Amersham. Arlington Heights. IL) and 20 jag/mL
poly(rC)»oligo(dG) template or poly(rA)«oligo(dT) template (Pharmacia), respectively.
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Two control reaction mixtures were also run with each set o f assays.. The positive
control contained 10 pL AMV RT and the negative control contained 10 pL sterile water.
The controls were included as samples for each run. and all samples were run in triplicate.
Using a timer, start times were staggered 15 seconds apart to give enough time to pipet
each sample correctly. The reaction mixture was incubated for 1 hour in a 37°C water
bath. The reactions were terminated by the addition o f 800 pL o f 10% trichloroacetic
acid (TCA. Fisher). Acid precipitable material was collected on Whatman GF/C fiber
discs, washed with 10 mL of cold 10% TCA and a final wash o f 2 mL o f 95% ethanol.
The filters were loaded into scintillation vials (F isher), 6 mL liquid scintillant (ICN
Biochemical. Costa Mesa. CA) was added to each vial, and the samples were counted in
a scintillation counter (Beckman Model LSI701). Background counts due to the reaction
cocktail were determined by counting 10 pL of reaction cocktail in 6 mL liquid
scintillation cocktail. The following formula was developed to determine the units o f
specific activity associated with each sample:
_______ CPM o f sample________

x(1.5x 10 ’) pmoles = pmoles activity in the

CPM o f 10 pi o f reaction cocktail

sample

There are 1.5 x 10'’ pmoles of [3H]dNTP/10 pL of reaction cocktail.

DETERMINATION OF PROTEIN CONCENTRATION
Protein concentration was determined by the Bradford assay technique using Pierce
Protein Reagent (Rockford, IL) (14). Bovine serum albumin (BSA) was used as the
standard. To determine the protein concentration o f reverse transcriptase purification
samples, protease and Pro-Pol protein purification samples, the 2 mg/mL BSA stock
solution was used to make a 200 pg/mL BSA working solution in RTB-50 or citrate
buffer (100 mM sodium citrate. pH 5.3. 5 mM EDTA. 1 M NaCl. and 1 mM DTT).
respectively. The 200 pg/mL solution was added to a series o f glass, disposable,
borosilicate test tubes (Fisher) containing MilliQ water to make standards within a 1-25
pg range. The final volume o f each o f these tubes was 1 mL. Simultaneously, 10-200 pi
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of each purification sample was added to a set of tubes tilled with MilliQ water to a final
solution volume of 1 mL. To determine the background due to buffer, a control sample
of 10-200 pL o f RTB-50 or citrate buffer was added to MilliQ water to a final volume o f
1 mL. I mL o f protein assay reagent was added to all o f the standards and the samples.
The solutions were mixed carefully, and each sample was transferred to a disposable,
plastic cuvette (Fisher). The absorbance of each standard was read at 595 nm where these
values were used to create a standard curve using C'A Cricket Graph III Software. The
absorbance due to the buffer was subtracted from the absorbance o f each sample read at
595 nm. The difference was applied to the equation for the linear regression line o f the
standard curve to determine the concentration o f the protein alone.

PREPARATION OF SAMPLES FOR SDS-PAGE
To prepare samples for electrophoresis, dilute samples were concentrated by TCA
precipitation. An aliquot of the fractions and/or pools was placed in a 1.5 mL eppendorf
tube. The sample was precipitated with a 100% solution o f TCA to a final concentration
of 10% TCA. The tube was vortexed and centrifuged for 5 minutes at 12.000 rpm. The
supernatant was decanted into a waste beaker and the pellet was washed three times with
1 mL 95% ethanol. The tube was centrifuged for 5 minutes for each wash and the
supernatant was discarded as before. The pellet was dried using the Speed Vac and
resuspended in 20 pL Tricine SDS sample buffer (450 mM Tris HC1. pH 8.45. 12%
glycerol. 4% SDS. 0.0025% Coomassie Blue G and 0.0025% Phenol Red) or NuPAGE™
SDS sample buffer (0.293 sucrose. 141 mM Tris Base, 106 mM Tris HC1, pH 8.5. 69.5
mM SDS. 0.51 mM EDTA. 0.22 mM Serva Blue G250 and 0.175 Phenol Red). 100 pL
of P-mercaptoethanoI was added to 1 mL o f either sample buffer prior to use. The
sample was then heated in a 90-100°C heat block for 10 minutes. For concentrated
samples, samples were mixed 1:1 with sample buffer and heated.
Additionally, the T7 tag positive control (Novagen) was prepared by adding 5 pL
control sample to 95 pL sample buffer (1:20 dilution). DNA Polymerase I (Promega) was
prepared by preparing a 1:100 dilution o f enzyme in sample buffer. 15 pL o f these
particular samples was loaded on the SDS-PAGE where indicated.
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SDS-PAGE
Pools from each step of the HTLV-1 RT purification and fractions from the partial
purifications o f protease and Pro-Pol protein were analyzed by SDS-PAGE. SDS-PAGE
was performed as described by Laemmli (59) or by a modification o f the procedure
described by Schaegger and von Jagow (113). 16% and 18 % acrylamide, Tricine gels
were prepared according to Table III. Where indicated, some o f the SDS-PAGE analyses
were performed using pre-cast 10-20% acrylamide Tricine gels from Novex (San Diego.
CA).
The Tricine running buffer was prepared as a I OX stock solution and stored at room
temperature. 80 mL o f the 10X solution was diluted with 720 mL MilliQ water to make a
IX Tricine running buffer solution (100 mM Tris. pH 8.3. 100 mM Tricine and 0.1 %
SDS) prior to each run. The acrylamide gel(s) was placed in the Xcell II™ Mini-Cell
(Novex) apparatus and the IX Tricine running buffer was poured in both the upper and
lower chambers o f the gel box. The gel was run at a 125 constant voltage for
approximately 90 minutes using the PowerPac200 (BioRad) power source.
A pre-cast NuPAGE ™ 4-12% Bis-Tris Gel (Novex) with 3-(N-morpholino)propane
sulfonic acid (MOPS) running buffer was used in the final analysis o f the HTLV-1 RT
purification. The running buffer was prepared by adding 40 mL o f 20X stock MOPS
buffer (Novex) to 760 mL MilliQ water to give a final concentration o f 50 mM MOPS.
50 mM Tris. pH 7.7. 3.5 mM SDS and I mM EDTA. 500 pL ofNuPAGE™ antioxidant
(Novex) was added to 200 mL o f the running buffer. This solution was poured into the
upper chamber o f the gel box. The remaining 600 mL o f running buffer was poured into
the lower chamber. The gel was run at a constant 200V for 50 minutes.
After any type o f run was complete, the gel was transferred to a clean glass container
and pre-washed in 200 mL MilliQ water for 1 hour at room temperature, with rocking.
The gel was then transferred to another tray filled with 20 mL Gelcode® Blue Stain
Reagent (Pierce. Rockford, IL) and incubated for 1 hour, with gently rocking. Finally,
the gel was transferred to another clean glass container and destained in 200 mL MilliQ
water overnight.
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TABLE III
Preparation o f Separating and Stacking Gels for SDS-PAGE Electrophoresis
Solution

16%
Acrvlamide
Separating Gel

18%
Acrvlamide
Separating Gel

4%
Acrvlamide
Stacking Gel

50% Acrylamide/BIS (29:l)a

2.0 mL

2.25 mL

250 pL

1M Tris-HCl. pH 8.8a

2.35 mL

2.35 mL

—

10 % SDSb

62.5 pL

62.5 pL

—

0.375 M Tris-HCl, pH 6.8a

—

1 mL

—

TEMED

1.6 pL

1.6 pL

1.2 pL

50 mg/mL Ammonium
Persulfatec

156 pL

156 pL

250 pL

50% Sucrose*1

1 mL

I mL

—

aAcrvlamide and Tris-HCl solutions were made as stock solutions and stored at 4°C.
bSDS and sucrose were also made as stock solutions and stored at room temperature.
'■'Ammonium persulfate was prepared fresh for each gel.
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WESTERN BLOTTING
Unless otherwise stated, all steps in the Western blot development procedure were
performed at room temperature. A second SDS-PAGE gel for transfer was run
simultaneously with the SDS-PAGE gel that was stained. After electrophoresis, proteins
in the second gel were transferred to a polyvinylidene difluoride (PVDF. BioRad)
membrane using a Trans-blot® SD Semi-Drv Electorphoretic Transfer Cell (BioRad). A
piece of PVDF membrane was cut to approximately the same dimensions o f the gel. The
membrane was dipped in methanol and then equilibrated in Western transfer buffer (25
mM Tris Base. 192 mM glycine and 30% methanol) for 30 minutes, with rocking. The
acrvlamide gel was also equilibrated in buffer for 30 minutes in a separate container.
The gel sandwich was prepared for transfer by placing a pre-wet (with transfer
buffer) piece o f thick blot absorbant filter paper (BioRad) on the platinum anode. A
disposable pipet was rolled over the surface of the filter paper to exclude all air bubbles.
The pre-wetted PVDF membrane was placed on top o f the filter paper. Bubbles were
removed with the pipet. The equilibrated gel was placed carefully on top o f the
membrane, aligning the gel in the center of the membrane. Another sheet o f pre-soaked
filter paper was placed on top o f the gel and air bubbles were removed again. The
cathode was placed on top o f the stack and the proteins on the gel were transferred to the
membrane at 18V for 50 minutes.
The sandwich was taken apart, layer by layer. If all o f the molecular weight
markers (low molecular weight. BioRad) transferred to the membrane, the blot
(membrane) was washed with Tris Buffered Saline (TBS. 20 mM Tris. pH 7.5 and 500
mM NaCl) for 5 minutes. To probe for HTLV-1 RT. the wash was removed from the
container and the blot was blocked by incubating the blot with 40 mL o f 3% gelatin/TBS
solution for one hour, with rocking. The blocking solution was removed and the blot was
washed again with Tween TBS (TTBS; TBS * 0.05% Tween-20) for 5 minutes. The
wash was again removed and the blot was placed in 40 mL 1% gelatin/TTBS with 5 pL
o fT 7 tag antibody (Novagen, 1:10.000 dilution) directed against the 10 amino acid gene
leader sequence peptide expressed by the pET translation vector and incubated overnight
with gentle rocking.
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The next morning, the antibody solution was removed and the blot was washed
twice with TTBS. 5 minutes each wash. The washes were removed and the blot was
incubated with the second antibody solution (40 mL TTBS with 13.2 pL Goat AntiMouse IgG (H + L) alkaline phosphatase conjugate. 1:3000 dilution. BioRad) for one
hour, with rocking. The solution was removed and the blot washed twice with TTBS and
once with TBS. 5 minutes each wash. Detection o f the antigen was performed using an
ImmunoBlot assay kit from BioRad. 300 pL o f Color Reagent A (NBT. nitroblue
tetrazolium in aqueous dimethlyformamide. containing magnesium chloride) and 300 pL
Color Reagent B (BCTP: 5-bromo-4-chloro-3 indoyl phosphate in dimethylformamide)
were added to 30 mL alkaline phosphatase color development buffer. After the last TBS
wash was removed, the blot was developed for 3 hours using the prepared alkaline
phosphatase color development buffer. Purple bands stained on the blot represent the
reverse transcriptase protein in the pET translation vector.
The Pro-Pol protein was transferred using the same methods, however, only one
antibody incubation was required. After transferring the gel. the blot was blocked byincubating the blot with 40 mL o f 1% gelatin/TTBS solution for 15 minutes, with
rocking. The blocking solution was removed and the blot was placed in 25 mL TBS with
5 pL of S-protein alkaline phosphatase conjugate antibody (Novagen, 1:5.000 dilution)
directed against the 15 amino acid S-Tag leader sequence peptide expressed by the pET
translation vector and incubated for 30 minutes with gentle rocking.
The antibody solution was removed and the blot was thoroughly washed 5 times
with 25 mL TTBS. 1-2 minutes each wash. Detection o f the antigen was performed using
an ImmunoBlot assay kit from BioRad. 332 pL o f Color Reagent A (NBT. nitroblue
tetrazolium in aqueous dimethlyformamide, containing magnesium chloride) and 336 pL
Color Reagent B (BCIP, 5-bromo-4-chloro-3 indoyl phosphate in dimethylformamide)
were added to 30 mL alkaline phosphatase color development buffer. After the washes
were removed, the blot was developed for 15 minutes using the prepared alkaline
phosphatase color development buffer. Purple bands stained on the blot represent the ProPol protein in the pET translation vector.
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Color development buffer was removed and the reactions were stopped by rinsing
the blots with deionized water for 10 minutes, changing the water every 5 minutes. The
blots were removed from the water and placed on paper towels to dry overnight. The
next morning, the blot was wrapped in plastic wrap and taped into a laboratory notebook
for future analysis.

PARTIAL PURIFICATION OF PRO-POL PROTEIN
The two 500 mL bacterial pellets were combined in a 50 mL conical centrifuge tube
and resuspended in 6 mL of lysis buffer (150 mM NaCl. 50 mM Tris. pH 8.0. 5 mM
imidazole) supplemented with 0.1% Triton X-100 and ImM PMSF. The solution was
kept on ice for 1 hour. The thawed pellet was vortexed vigorously and DNA was sheared
with a sonic dismembrator with 6-10 second pulses and 10 second cooling between
pulses. The suspension was cleared by centrifugation for 20 minutes at 10.000 RPM at
4°C to remove insoluble debris. The crude supernatant was used for the subsequent
purification steps.
V i+--NTA Affinity Chromatography
Unless otherwise stated, all steps were carried out at room temperature. The crude
supernatant was incubated, with rocking, with I mL o f N i'2-NTA slurry (Qiagen.
Valencia. CA). After one hour, the entire solution was poured in a column ( 8 cm x 1.5
cm i.d.) and the pass fraction was collected. The column was eluted with a stepwise
gradient o f 5 mL 10 mM imidazole. 5 mL 50 mM imidazole, four 1.25 mL 100 mM
imidazole washes and 2 mL 500 mM imidazole. Each imidazole wash was prepared in
buffer containing 150 mM NaCl and 50 mM Tris, pH 8.0). The fractions were analyzed
by SDS-PAGE. The fractions containing the majority o f the protein were pooled and
dialyzed against 500 mL lysis buffer (without PMSF and Triton X-100) for four hours,
where the buffer was changed at the 2 hour interval.
S-tag agarose chromatography
The entire protein pool from the N i'2 purification step was incubated, with rocking, with
1 mL S-tag agarose beads (Novagen) for 30 minutes in a 14 mL round bottom,
polystyrene tube. Recovery o f S-tagged peptide was achieved by following the
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manufacturer's protocol (Novagen). The pass fraction was collected by centrifuging the
tube, containing the agarose beads and protein, at 500 x g for 10 minutes. The beads
were allowed to settle and the supernatant was carefully removed with a pipet so as not to
disturb the beads. The supernatant was transferred to a test tube and labeled as the pass
fraction. The beads were then washed by resuspending the agarose beads in 5 mL
bind/wash buffer (50 mM NaCl. 20 mM Tris. pH 8.0. and 0.1% Triton X-100). The
mixture was mixed by repeated inversion, followed by centrifugation at 500 x g for 10
minutes. The supernatant was removed with a pipet and transferred to separate test tubes.
The beads were resuspended twice more in the same manner, and the supernatants were
saved as low salt washes.
To elute the Pro-Pol protein, the S-protein agarose beads were resuspended in 1.5
mL 3 M MgCL and the mixture was incubated for 10 minutes, with gentle rocking. A 5mL capacity spin filter, provided by the manufacturer, was placed in a 15 mL sterile,
centrifuge tube. The incubated mixture was poured into this spin column, fhe bound
protein was dissociated from the agarose by centrifuging the spin column/centrifuge tube
assembly at 500 x g for 5 minutes. An additional 1.25 mL o f 3 M MgCL was added to
the spin filter. The assembly was centrifuged again at 500 x g for 5 minutes. A 100 pL
aliquot of the filtrate was saved for SDS-PAGE analysis while the remainder o f the
filtrate was dialyzed against 500 mL Bind/Wash buffer for 4 hours using 7.000 MWCO
dialysis tubing (Pierce). The buffer was changed at two hours. The dialvsate was then
concentrated 10-fold using an 3.000 MWCO Centricon-3 microconcentrator (Amicon.
Danvers. MA). The concentrator was placed in a 14 mL centrifuge tube. The dialysate
was placed in the concentrator/centrifuge tube assembly and centrifuged at 6500 RPM for
3 hours. The final volume o f the concentrate was 300 pL. Fractions from each step o f
the purification scheme were analyzed by SDS-PAGE and Western blotting.

EXPRESSION OF ACTIVE PROTEASE
The removal o f inclusion bodies and the solubilization o f the protease was performed
using a modified protocol o f a published procedure (19). Briefly, the bacterial pellet was
resuspended in 1 mL o f buffer A (500 mM NaCl. 20 mM Tris, pH 8.0, 5 mM imidazole).
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The solution was kept on ice for 1 hour. The thawed pellet was vortexed vigorously and
the suspension was centrifuged at 10,000 RPM for 25 minutes. The insoluble fraction
was resuspended in another 1 mL o f buffer A. vortexed vigorously and centrifuged again
to further remove inclusion bodies. The insoluble fraction was resuspended in 2 mL
buffer B (buffer A + 8 M urea) and the DNA was sheared with a sonic dismembrator
using 6 -1 0 second pulses with a 10 second cooling period between pulses. Finally, the
suspension was cleared by centrifugation for 20 minutes at 12.000 RPM at 4°C to remove
insoluble debris. The supernatants from the first two centrifugation steps were saved for
SDS-PAGE analysis. The final crude supernatant was used for the subsequent
purification steps.
.Vi+--NTA affinity chromatography
Unless otherwise stated, all steps were carried out at room temperature. The crude
supernatant was incubated, with rocking, with I mL o f Ni :-NTA slurry. After one hour,
the entire solution was poured in a column ( 8 cm x 1.5 cm i.d.) and the pass fraction was
collected. The column was developed with a stepwise gradient o f four I mL 20 mM
imidazole washes and the protein was eluted with 2 mL of 1 M imidazole. The imidazole
washes were prepared in buffer containing 500 mM NaCl. 20 mM Tris, pH 8.0. 8 M urea.
Refolding and activation o f protease
A 100 pL aliquot o f the eluate fraction was saved for SDS-PAGE analysis. To refold and
activate the protease in the eluate. a sequential dialysis was performed. The protease was
dialyzed against 500 mL acetate buffer (10 mM sodium acetate. pH 3.5 and I mM DTT)
for 4 hours using a 3 mL. 7.000 MWCO Slide-A-Lvzen® dialysis cassette from Pierce.
The buffer was changed after 4 hours, and the protein was allowed to dialvze overnight
for another 12 hours in acetate buffer. The next morning, the dialysis cassette was placed
in 500 mL citrate buffer (100 mM sodium citrate. pH 5.3. 5 mM EDTA. 1 M NaCl and 1
mM DTT). The buffer was changed at the end o f the day and the protein was again
dialyzed overnight. The total acetate dialysis time was approximately 24 hours.
Protease activity assay
200 pL o f refolded protease was pipetted in a 10 mm quartz cuvette (Stama Cells) and
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incubated for 10 minutes at 37°C in a thermostatically adjusted Luminescence
Spectrophotometer (Perkin Elmer. Model LS50B). The cuvette was removed from the
cell chamber and the cleavage reaction was initiated by the addition o f 480 pL 100 mM
sodium citrate buffer and 5 pL substrate( 15 mM). The reaction was mixed by gentle
inversion and the cuvette was replaced in the cell chamber. Hydrolysis o f the synthetic
substrate Abz-KTKVLVVQPK-(3NO:Y)A (custom made at the University o f
Michigan), which contains the cleavage site of HTLV-1 p24/pl5 between the underlined
leucine and valine, was characterized by measuring the fluorescence emission spectra of
the sample at 450 nm/2.5 nm bandpass at an excitation o f 320 nm/15 nm bandpass. Data
points were collected over a period o f 30 minutes using FL WinLab Software (Perkin
Elmer. Norwalk. CT).

IDENTIFICATION OF THE PRO-POL PROTEIN PROCESSING SITE
100 pL o f activated protease in citrate buffer (0.05 pg/pL) was incubated with
200 pL Pro-Pol protein (0.67 pg/pL) overnight in a 37°C heat block to cleave the Pro-Pol
protein in lysis buffer. Control samples. 100 uL protease in citrate buffer only and 200
pL Pro-Pol protein only, were also incubated overnight at 37°C.
Hydrolysis o f the substrate, which contains the putative proteolytic processing site
at the N-terminus o f HTLV-1 RT was analyzed by SDS-PAGE and Western Blotting.
The cleavage reaction samples were separated by SDS-PAGE using either an 18%
acrvlamide Tricine gel or 10-20% acrylamide gradient Tricine gel. One gel was
transferred to a PVDF membrane for Western blotting as described previously.
All steps in the following staining procedure were performed at room temperature.
The second gel was fixed in 100 mL fixing solution consisting o f 50% methanol. 10%
acetic acid and 40% MilliQ water for 10 minutes, with rocking. The gel was then stained
using solutions from a Colloidal Blue CoomassierM Staining Kit (Novex). The gel was
placed in staining solution containing 55 mL MilliQ water. 20 mL methanol and 20 mL
Stainer A (ammonium sulfate and phosphoric acid) for 10 minutes. 5 mL o f Stainer B
was added to the staining solution and the gel was allowed to rock for 3 hours. The gel
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was then transferred to a glass tray container with 200 mL MilliQ water and allowed to
destain overnight.
The entire gel was sealed in a heat-sealable bag. The gel and a Polaroid picture o f
the gel denoting the band o f interest was sent to the W.M. Keck Biomedical Mass
Spectrometry Laboratory. Biomolecular Research Facility. University o f Virginia.
Charlottesville. Virginia. Dr. Nicholas E. Sherman cut the band out o f the gel and
digested the sample with trypsin. Extracts were combined and evaporated to 25 pL for
LC-MS analysis.
Mass analysis and sequence analysis
The masses o f the peptides o f interest from the enzymatic digest were determined by LCMS using a Finnigan LCQ ion trap mass spectrometer system with a Protana nanospray
ion source interfaced to a self-packed 8 cm x 75 pm i.d. Phenomenex Jupiter 10 pm C18
reversed-phase capillary column. 0.5-5 mL volumes o f the extract were injected and the
peptides eluted from the column by an aeetonitrile/0.1 M acetic acid gradient at a flow
rate o f 0.25 pL/min. The nanospray source was operated at 2.8 kV. The digest was
analyzed using the double play capability o f the instrument to obtain full scan mass
spectra and product ion spectra in sequential scans. In this manner, both peptide
molecular weight and the amino acid sequence was determined. The data was analyzed
by database searching using the SEQUEST search algorithm. Peptides that were not
matched by this algorithm were interpreted manually and searched versus the EST
databases using the SEQUEST algorithm.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

46

CHAPTER III
RESULTS: PURIFICATION OF RECOMBINANT HTLV-1 RT

Detailed analysis o f the properties o f HTLV-1 RT have been limited by the small
quantity o f enzyme which can be isolated from retroviral virions. An alternate means to
prepare the enzyme is to express the pol gene in E. coli. allowing overproduction o f the
protein and facilitating further characterization. Two clones o f HTLV-1 RT were
constructed by Dr. Laura Moen (Fig. 5) in our laboratory. Expression o f the full length
clone in E. coli strain W 311U(DE3) was successful and this protein was used for the work
described in subsequent sections.
The experimental approach to isolate the recombinant HTLV-1 RT utilized adsorption
chromatography, a common feature for most polymerase purification procedures.
Proteins bind to the exchanger resins by electrostatic forces. To determine the optimal
conditions for adsorption, the stability range o f the HTLV-1 RT. pH = 7.0-8.0 and its
isoelectric point (pi) = 9.0 were considered. Scientists suggest using a cation exchanger
for polymerases that are stable at neutral pH ranges and an anion exchanger for
polymerases that are more stable at basic pH ranges. For a pi « 8.5. a cation exchanger is
also recommended (106. 112). Since the HTLV-l RT has an optimum pH within a
neutral and basic pH range, both a cation exchanger (phosphocellulose; P-l 1) and an
anion exchanger (diethylaminoethyl cellulose; DEAE) were investigated.
Purification schemes of other reverse transcriptases (HIV-1 RT. BLV RT. AMV RT
and MMTV) were also analyzed to determine a comparable purification scheme for
recombinant HTLV-l RT. Phenyl sepharose. heparin sepharose and DNA cellulose
affinity columns and sepharose gel filtration media were also investigated for fiirther
optimization o f purification parameters.. All o f these techniques for purification o f
polymerases utilize a different property o f interaction with the proteins to facilitate
isolation. Thus, presumptions can be made as to the amino acid composition o f the active
site o f the enzyme based on the information obtained from each application.
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PRELIMINARY TRIALS
Initially, all trials with each type o f resin were performed using small columns (1 mL
-50 mL), stepwise gradients and 0.5-1 L bacterial cell pellets. As shown in Appendix B.
the DEAE cellulose anion exchanger did not fare well with our protein. SDS-PAGE
analysis and Western blotting indicate that the protein did not stick to the column. The
majority of the RT activity was found in the pass fraction. SDS-PAGE analysis o f a
phosphocellulose (P -l 1) purification o f the enzyme shows a much cleaner preparation
compared to the DEAE purification (Fig. 7). Consequently, the DEAE column was not
considered for the purification scheme.
SDS-PAGE analysis of the P-l 1 purification further indicates that the protein eluted
at 0.2-0.3 M K.C1 using a stepwise gradient, however, the fractions were not pure. Further
purification o f the protein was attempted by utilizing either a heparin sepharose CL-6B.
phenyl sepharose CL-4B or DNA cellulose. Each resin was prepared according to the
manufacturer's instructions and poured as a media slurry in a small column (3-5cm x 1.5
cm i.d.). Either the 0.2 M or 0.3 M K.C1 fraction from the P-l 1 column was applied to the
column.
O f the three resins that were investigated, the heparin sepharose gave the best results.
As shown in Fig. 8A. a high molecular weight protein in agreement with the predicted
size o f the protein eluted in both the 0.1 M and 0.5 M K.C1 fractions. Western blot
analysis demonstrates that the HTLV-l RT appears only in the 0.5 M KC1 fraction (Fig.
8B). Earlier efforts to use the heparin sepharose column indicated that the high molecular
weight protein also eluted in the 0.5 M K.C1 fraction, and this protein was more pure than
the 0.3 M K.C1 fraction from the P-l 1 step. However, the protein did not appear in the
Western blot, indicating that the high molecular weight protein was not the HTLV-1 RT.
To clarify this inconsistency and to determine the concentration at which the HTLV-1 RT
elutes, a linear gradient o f 0.1-1.0 M KC1 was applied to the column instead o f the usual
stepwise gradient. Several different peaks o f RT activity were observed in all o f the
preparations. Analysis of these peaks by SDS-PAGE and Western blotting proved
inconclusive as no consistency in gel band patterns could be established. Also, the high
molecular weight protein did not consistently appear on the Western blot.
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FIG . 7. SDS-PAGE analysis o f a phosphocellulose (P-l 1) purification and a DEAE
purification. Crude lysate is compared with eluate from each stepwise elution for P -11
(A) or DEAE (B). The arrow points to recombinant HTLV1-RT.
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FIG. 8. SDS-PAGE analysis of heparin sepharose column fractions. Fractions were
subjected to electrophoresis on 10% acrvlamide gels and either (A) stained with
Coomassie Brilliant Blue or (B) transferred to a PVDF membrane for Western blotting.
The arrow points to the recombinant HTLV1-RT. Coomassie Brilliant Blue or (B)
transferred to a PVDF membrane for Western blotting. The arrow points to the
recombinant HTLV1-RT.
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The phenyl sepharose column served two purposes in these preliminary trials: (1) to
further purify the HTLV-l RT, and (2) to determine if there were any hydrophobic
regions in the polymerase. Coomassie stained SDS-PAGE gels o f the phenyl sepharose
fractions indicated that a protein o f Mr = 99,000 was present in the 0.6 M- 0 M NH4S 0 4
fractions yet the protein did not light up on the Western blot (Fig. 9). After repeated cell
preparations and similar results, it was concluded that the protein may have bound to the
resin yet becomes too dilute throughout the elution process such that it does not appear on
the blot. Another E. coli protein may have co-eluted with our protein making the 99.000
Da band appear concentrated. To evaluate this hypothesis, another preparation was run
whereby the protein, if present, was eluted off the column with one 0 M NH4S 0 4 elution.
This pool was concentrated and analyzed by SDS-PAGE and Western blotting. The
protein band still did not appear in the concentrated fraction. Thus, use o f the phenyl
sepharose column as a second step for purification o f the enzyme was terminated.
The SDS-PAGE analyses of the DNA cellulose fractions did not give any
encouraging results. Most gels showed that the protein did not stick to the column as the
protein was found in the pass fraction. Figure 10 also illustrates that the pass fraction is
not much cleaner than the 0.2 M K.CI fraction from the P-l 1 step.
After performing several preparations, the resin that would optimize purification o f
the P-l 1 fraction/pool was found to be the gel filtration media, sepharose CL-6B
(Pharmacia). The overall purification scheme, depicted in Fig. 11. requires a 5 L
bacterial culture preparation containing the expression plasmid. The protein was eluted
from a 400 mL P-l 1 column using a linear gradient. The column volumes were
increased 8-fold from the original 50 mL column in order to recover a sufficient amount
o f protein for biochemical characterization.

PURIFICATION OF THE RECOMBINANT PROTEIN
The purification procedure, summarized in Table IV. involves only two steps with
minimum inactivation o f enzyme activity during purification. This procedure results in
the purification of the recombinant protein to approximately 90% homogeneity (Fig. 12).
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FIG. 9. SDS-PAGE analysis of phenyl sepharose column fractions. Fractions were
subjected to electrophoresis on 10% acrvlamide gels and stained with Coomassie Brilliant
Blue. The arrow points to the recombinant HTLV1-RT.
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FIG. 10. SDS-PAGE analysis o f DNA cellulose column fractions. Fractions were
subjected to electrophoresis on 10% acrvlamide gels and stained with Coomassie Brilliant
Blue. The arrow points to recombinant HTLV1-RT.
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F IG . 11. HTLV-I RT purification scheme. The purification o f the recombinant HTLV-1
RT involves a two-step chromatographic process involving a cation exchanger,
phosphocellulose and a gel filtration column, sepharose.
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TABLE IV
Purification o f Recombinant HTLV-1 RT and Associated Activity
Pool

Volume
(mLs)

Total
ProteinJ

% Total
Protein

Specific
Activity
U/pgb

£ coli lysate

170

1000 mgb

100

.11

I

phosphocellulose

69

856 pg

<0.1

24.8

II

sepharose

23

33 pg

<0.1

3.45

Purification Step

J Bradford Method used (14)
b One unit is the amount o f enzyme required for the incorporation of 1 pmole o f
labeled dGMP in one hour at 37°C.
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FIG. 12. Analysis and purification o f HTLV-1 RT by SDS-PAGE. Samples from
various stages o f the purification were subjected to electrophoresis through a 4-12% BisTris gel from Novex and the proteins were detected by staining with Gelcode blue as
described (2). Lane M. Markers. Lane I. crude ex tra ct. Lane 2. pooled phosphocellulose
fraction. Lane 3. sepharose pool. The position o f marker proteins are indicated at the
sides. The arrow points to the band at the correct size o f the full length translation
product o f pETab3.
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Phosphocellulose chromatography
Initially, the bacterial cell pellet containing the recombinant HTLV-1 RT was lysed in
50mM Tris. 8% sucrose. 50mM EDTA. 5% Triton X-100. 10 mg/mL lysozyme and
chromatographed on a P-l 1 column. The majority o f the reverse transcriptase eluted as a
peak at approximately 0.3-0.5M K.C1 (Fig. 13A). Phosphocellulose chromatography was
the single most important step in the purification resulting in the greatest increase in
specific activity: total recovery in this step was. unfortunately, rather low (<0.01%).
Sepharose Molecular Sieve
The phosphocellulose peak fractions o f RT activity were pooled and applied to a
sepharose CL-6B column. By comparing elution volumes o f peaks to the standard curve
shown in Appendix A, it was determined that the RT activity eluted as 2-3 separate peaks
with varying molecular weights (Fig. 13B). To determine which of these pooled fractions
contains the recombinant protein, samples from the protein fractions were analyzed by
SDS-PAGE. and the proteins were visualized by staining with either Coomassie or
Gelcode Blue. A major band (Mr = 82.000-104.000) was found in the third sepharose
pool (Fig. 12). Since the location o f the band in the gel is in agreement with the
estimated size o f our protein and has the expected activity, the pool was concentrated for
further analysis.

STABILITY STUDIES
Figure 14A shows a comparison o f the activities o f pooled fractions at different stages
of purification. A 60-fold increase in RT activity was consistently observed after the
cmde extract was passed through the phosphocellulose column. However, by the time
the sepharose fractions (eight days) were pooled and recovered, the protein had lost 8090% of its activity.
Time and Temperature
To determine whether the activity loss was due to the temperature conditions at which the
samples were stored or if the activity loss was solely due to the duration o f time that had
passed, aliquots o f the sepharose pools were stored at three different temperatures: 4°C.
20°C and -80°C. No significant difference in activity was calculated when sepharose
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FIG. 13. Purification elution profiles. (A) Phosphocellulose elution profile. The crude
extract was chromatographed on P-l I (20 x 5 cm i.d.) as described in the text. Activity
o f fractions (■) was determined over the range o f fractions eluted with a linear gradient
( • ) . The arrow indicates the fractions containing the recombinant protein. (B) Sepharose
elution profile. The concentrated P-l I pool was applied to a sepharose 6CL-B column
(52 x 5 cm i.d.). Aliquots o f individual fractions were assayed for reverse transcriptase
activity as described in Materials and Methods. The arrow indicates peak activities at (I)
640 kDa, (II) 540 kDa and (III) 99 kDa.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

58

A

Crude
DAY 1

DAY 3

DAY 8

B

+4 C

-20 C

-8 0 C

Temperature

FIG. 14. Template and stability studies. RT activity was assayed as described in
Materials and Methods. Black boxes represent poly(C)«oligo(dG) template. Gray boxes
represent poly(A)*oligo(dT). (A) Stability over time was tested as described on 10 pL
samples from each stage of purification. (B) Aliquots of the sepharose pool were stored
at three temperatures: 4°C, -20°C and -80°C.
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samples were stored at different temperatures (Fig. 14B). This pattern appears to be time
dependent and was seen at all stages o f purification. The addition or elimination o f
reducing agents did not have any effect on the rate o f activity loss. Activity could not be
recovered by reconstitution with the other sepharose pools.
To enhance the stability o f the P-l 1 pool before the pool is applied to the sepharose
column, complete dehydration of the P-l 1 pool by speed vacuum drying or lyophilization
was suggested. Aliquots o f the P-l 1 pool were either dried using the speed vacuum in
our laboratory or shell-frozen in liquid nitrogen and lyophilized at Eastern Virginia
Medical School. The aliquots were then stored at -70°C. The samples were reconstituted
in RTB-50 and RT activity was measured over a period o f one week.
Figures 15 and 16 compare the RT activity o f a P-l 1 pool stored at the same
temperatures investigated earlier as well as speed vacuumed and lyophilized samples.
The graphs illustrate that P-l 1 pools are not stable in any particular storage condition. In
Fig. 16. the P-l 1 pool dropped to 67% o f the original activity when speed vacuumed dry.
The sample that was frozen in liquid nitrogen and stored at -70°C dropped similarly to
72% o f the original activity. As expected, almost all samples dropped in activity after a
w eek's time had passed. In some cases, activity dropped to almost 30% o f the P-l 1 pool
activity. In other preparations, this decrease was not seen at all which adds to the overall
inconsistency o f storage conditions. Results o f this study indicate that perhaps the
protein's activity is intrinsically low or that the protein exists in an unfavorable folded
state. These speculations will be farther addressed in a subsequent section.

TEMPLATE SPECIFICITY
As shown in Figs. 14A and 16. reverse transcriptase activity was also investigated
with three synthetic homopolymeric templates. poly(rA)«oligo(dT), poly(rC)»oligo(dG)
and poly(dA)«oIigo(dT). In earlier studies o f template specificity, only
poIv(rA)«oligo(dT) and poly(rC)«oligo(dG) were analyzed. The recombinant protein
does not have a strong preference for either synthetic template (Fig. 14A). However, the
recombinant protein in the phosphocellulose pool did prefer the poly(rA)*oligo(dT)
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FIG. 15. Stability of P-l 1 pools. RT activity of P-l 1 pools stored at different
temperatures and conditions was measured. After the P-l 1 pool was dialyzed, it was
stored in 50 pi aliquots at various temperatures.
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FIG. 16. Re-examination of the stability of the P-l 1 pool. Another P-l 1 preparation
was further analyzed to assess its stability when stored as a speed vacuumed sample
a liquid N2frozen sample. Shaded boxes represent poIy(C)«oligo(dG) template. Open
boxes represent poly(A)«oligo(dT).
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template over the poly(rC)«oligo(dG) with a 3-fold increase in nucleotide polymerization
(Fig. 14A). Analysis o f crude extracts carrying the plasmid by polyacrylamide gel
electrophoresis (Fig. 12) indicated that many proteins were being synthesized that could
contribute to the activity o f the protein. The increase in activity was attributed to cellular
polymerase interference, particularly E. coli Pol I. which has a greater affinity for the
poly(rA)»oIigo(dT) template.
E. coli DNA PO LY M ER A SE I
Other research reports have confirmed that highly purified DNA polymerase I o f
E. coli. when presented with a polv(rA)«polv(dT) template, can form poly (dT) with a
high efficiency (5. 51. 100). Furthermore. poly(rA)»poly(dT) is an equally effective
template for both viral and cellular DNA polymerases, and therefore cannot be used to
distinguish reverse transcriptase activity from that o f other DNA polymerases (101). In
contrast, when the same group tested the synthetic oligomer-homopolymer templates,
such as po!y(rA)*poly(dT) and po!y(dA)*poly(dT). the viral reverse transcriptase could
clearly be distinguished from the cellular DNA polymerase. The AMV RT and MasonPfizer monkey virus (M-PMV) showed a preference for the polv(rA)«poIy(dT) while the
E. coli DNA Pol I showed a preference for the poly(dA)«poly(dT) template.
As previously stated, the recombinant HTLV-1 RT did not show any template
specificity when comparing synthetic hybrid templates. The increase in activity seen in
the P-l 1 pool while using the poly(rA)*polv(dT) template may be due to interferences
from the E. coli DNA Pol I. Moreover, E. coli DNA polymerase has an approximate Mr
= 109,000 Da. In Fig. 12. the recombinant HTLV-1 RT protein appears between the 87
kDa and 120 kDa molecular weight markers. Since SDS-PAGE provides a relative
estimation o f molecular weight, it is possible that the E. Coli DMA polymerase was
purified, not the HTLV-1 RT, which may explain the increase in activity in the P-l 1 pool
and decrease in the sepharose pool. To examine this possibility, the high template
specificity o f E. coli DNA Pol I for a poly(dA)«poly(dT) template was confirmed by
making serial dilutions o f pure E. coli DNA Pol I (Promega). The polymerase activity o f
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each dilution was measured using three templates: poly(rA)«oligo(dT),
poly(rC)*oligo(dG) and poly(dA)»oligo(dT). Figure 17 illustrates that E. coli DNA Pol I
has a high specificity tor a poly(dA)«oligo(dT). The polymerase activity with this
template is a 5-50-fold increase o f the activity obtained from a poly(rC)*oligo(dG)
template. With every subsequent preparation, activity assays were performed using both
of these templates. The ratio o f activity o f poly(dA)«oligo(dT)/ polv(rC)«oIigo(dG) of
subsequent preparations was approximately 1.1-1.5 indicating that most likely the activity
seen in the different purification steps is from the recombinant HTLV-l RT.
To further confirm that the protein isolated was HTLV-l RT. the migration
pattern o f a 1/100 dilution of E. Coli DNA Pol 1 was analyzed on an SDS PAGE gel and
compared to the migration pattern o f purified HTLV-l RT. Figure 18 illustrates that the
E.coli DNA Pol I does indeed migrate at a higher molecular weight than the recombinant
HTLV-l RT protein. Further analysis by Western blotting indicated that there was no
cross reactivity with the T7 tag antibody. The E. coli DNA Pol I enzyme did not appear
in the Western blot.
Still, the stability issue has not been resolved. The protein may not maintain its
native, active form due to improper folding o f the enzyme. The N-terminus o f the reverse
transcriptase may play a role in the proper folding o f an active enzyme. For example, in
HIV-1 RT. the 20 amino-terminal amino acids are absolutely required for its
polymerization activity (42). Therefore, by identifying the authentic N-terminus o f the
HTLV-l RT. a basis for the structural analysis o f the enzyme can be established. Further
investigation o f the correct N-terminus would allow for a better understanding o f folding
differences that may explain the low stability of the enzyme.
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FIG. 17. Activity assay of E. coli DNA Polymerase I. Pure E. coli DNA Pol I
(Promega) was diluted in RTB-50: 1:10,000; 1:1,000; 1:100, 1:10; 1:5. The polymerase
activity was measured for each diluted sample using three different templates:
poly(rA)«oligo(dT), poly(rC)«oligo(dG) and poly(dA)*oligo(dT).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

65

M
A

1

VI

103kD---- ■ * -------- <■

104kD----- «

76kDa— •

81kDa----- |

49kD

33kD

2

ft

4 8 k D -----

28kD

19kD

35kD
28 k D

§
*

FIG. 18. SDS-PAGE analysis o f E. coli DNA Polymerase I. Fractions were subjected to
electrophoresis on a 16% Tricine gel and stained with Gel Code Blue. (A) Lane M.
Markers. Lane 1, DNA Pol 1 (B) Lane M. Markers. Lane 2. concentrated sepharose pool.
The position o f marker proteins are indicated at the sides. The black arrow points to E.
coli DNA Polymerase I and HTLV1-RT. respectively.
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CHAPTER IV
RESULTS: IDENTIFICATION OF THE N-TERMINUS
OF HTLV-l RT

Translation o f the retroviral reverse transcriptases in the pol region is a complex
process because o f the occurrence o f frameshift events. The first reading frame o f the
genomic RNA encodes for the Gag protein. The first frameshift event results in a GagPro polyprotein precursor. In some retroviruses, such as BLV. a second frameshift occurs
resulting in the synthesis o f a Gag-Pro-Pol polyprotein precursor. These precursors must
be cleaved by viral protease to produce the Pol related enzymes (16, 151).
Little is known about the cleavage sites o f HTLV-l protease, particularly in the
pol region. HTLV-l is closely related to HTLV-2 and BLV, and their sequences show a
high degree o f homology at the DNA and protein level (52, 84). Perach et al. determined
the amino terminus o f BLV RT matches the last 26 codons o f the pro gene and is coded
for by the pro reading frame (92). As discussed earlier. HTLV-l also uses two successive
frameshifts to form its Pol polyprotein. Thus, an analogous cleavage position in the ProPol precursor would create a Pol protein with the first 25 amino acids being derived from
the protease reading frame.
Published alignments between the protein sequences o f the reverse transcriptases
o f HTLV-l and HIV-1 (52) begin the comparison at the first amino acid after the pro-pol
frameshift in HTLV-l at a position 27 amino acids downstream from the known amino
terminus o f H IV -1 RT (25, 61). However, an alignment beginning at the first N-terminal
amino acid o f HIV-1 RT with the proposed HTLV-l coding sequence which includes the
extra 25 amino acids from the pro ORF shows significant similarity. Figure 6 shows this
homology comparison and includes equivalent regions from both HTLV-l and BLV as
well. Thus, based on the above evidence, the amino terminus o f HTLV-l RT is believed
to be amino acid number 158 at the pro ORF (100), 25 amino acids upstream o f the
frameshift into the po l ORF. This cleavage site corresponds to Leul57-Pro158 in the pro
ORF.
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To identify the authentic amino terminus o f the H TLV -l RT. Dr. Laura Moen
constructed a clone using the same strategy as that used to clone the HTLV-l RT (Fig. 5)
to produce a protein fragment composed o f the amino acids from the C-terminal region o f
the protease up through the amino acids in the frameshift region o f the pol ORF. The
Pro-Pol protein is approximately 11,700 Da and contains the region tentatively identified
as the cleavage site based on the sequence alignments (Fig. 19).

PREPARATION OF SAMPLES FOR CLEAVAGE ASSAY
Partial purification o f the Pro-Pol protein fo r the cleavage assay
The protein was partially purified using a N i': affinity column and an S-tag agarose resin
as described in the methods section. As shown in Fig. 20A, the majority o f the Pro-Pol
protein eluted in the 50 mM imidazole and the first two 100 mM imidazole washes.
These fractions were further purified with S-tag agarose to approximately 70%
heterogeneity (Fig. 20B. lane 6).
Refolding a n d activation o f protease
Before the HTLV-l protease clone could be utilized for processing o f the Pro-Pol
protein, it was first refolded and activated in low pH buffers. The HTLV-l protease
functions as a dimer, composed o f two identical monomeric subunits. Each monomeric
subunit has a Mr= 14.000. In vivo, protease activation occurs via excision o f the protease
monomer from the Gag-Pro precursor followed by dimerization o f the monomeric units.
Dimerization is essential for its enzymatic activity (39). The protease construct was
partially purified following an already published procedure for in vitro activation (19).
The sequence for the protease construct is depicted in Appendix C. As shown in Fig. 21.
the expressed protease construct migrated at a higher m olecular weight (Mr=28.000) than
the weight predicted for the monomer. This occurrence can be attributed to the histidine
tag which carries a positive charge. The massxharge ratio becomes altered resulting in
the slower migration o f the protein. Still, the protease was expressed in both the
insoluble precipitate in the dialysate and the supernatant (lanes PPT and R). The size of
this expression product suggests that the protease did not completely autoprocess (i.e. the
histidine tag was not completely processed during dialysis), yet, protease activity
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10
20
30
40
ATG AAA GAA ACC GCT GCT GCT AAA TTC GAA CGC CAG CAC ATG GAC
TAC TTT CTT TGG CGA CGA CGA TTT AAG CTT GCG GTC GTG TAC CTG
Met Lvs Glu Thr Ala Ala Ala Lvs Phe Glu Arg Gin His Met Asp
50
60
70
80
90
AGC CCA GAT CAG GGT ACC CTG GTG CCA CGC GGT TCC ATG GCC ATC
TCG GGT CTA GTC CCA TGG GAC CAC GGT GCG CCA AGG TAC CGG TAG
Ser Pro Asp Gin Gly Thr Leu Val
Pro Arg Gly Ser Met Ala
lie
100
110
120
130
ATA GGT CGT GAT GCC TTA CAA CAA TGC CAA GGC GTC CTG TAC CTC
TAT CCA GCA CTA CGG AAT GTT GTT ACG GTT CCG CAG GAC ATG GAG
lie Gly Arg Asp Ala Leu Gin Gin Cvs Gin Gly Val Leu Tvr Leu
140
150
160
170
180
CCT GAG GCA AAA GGG CCG CCT GTA ATC TTG CCA ATA CAG GCG CCA
GGA CTC CGT TTT CCC GGC GGA CAT TAG AAC IGGT TAT GTC CGC GGT
Pro Glu Ala Lvs Glv Pro Pro Val lie Leu Pro lie Gin Ala Pro
190
200
210 '
220
GCC GTC CTT GGG CTA GAA CAC CTC CCA AGG CCC CCC GAA ATC AGC
CGG CAG GAA CCC GAT CTT GTGGAG GGT TCC GGG GGG CTT TAG TCG
Ala Val
Leu Glv Leu Glu His Leu Pro Aru Pro Pro Glu lie Ser
230
240
250
260
270
CAG TTC CCT TTA AAC CCA GAA CGC CTC CAG GCC TTG CAA CAC TTG
GTC AAG GG A AAT TTG GGT CTT GCG GAG GTC CGG AAC GTT GTG AAC
Gin Phe Pro Leu Asn Pro Glu Arg Leu Gin Ala Leu Gin His Leu
280
290
300
310
GTC CGG AAG GCC CTG GAG GCA GGC CAT CTC GAG CAC CAC CAC CAC
CAG GCC TTC CGG GAC CTC CGT CCG GTA GAG CTC GTG GTG GTG GTG
Val Arg Lvs Ala Leu Glu Ala Glv His Leu Glu His His His His
320
CAC CAC TGA
GTG GTG ACT
His
His ***

FIG. 19. Amino acid sequences o f the HTLV-l Pro-Pol protein. The Pro-Pol protein
sequence spans a region where the HTLV-l protease is known to terminate. Isol,:-Leu15
(86), and continues past the pro-pol frameshift site. (----- ) dotted lines represent the
putative cleavage site. Boxed amino acid sequence represents the region o f the second
frameshift.
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FIG. 20. Analysis o f the purification steps o f the Pro-Pol protein by SDS-PAGE. (A)
N i’:-NTA affinity fractions o f the Pro-Pol protein purification were subjected to
electrophoresis through a 16% Tricine gel and the proteins were detected by staining with
Gelcode blue. Lane 1. crude e x tra ct. Lane 2. pass. Lane 3. 10 mM imidazole wash.
Lane 4. 50 mM imidazole wash. Lanes 5-8. 4 sequential 100 mM imidazole washes.
Lane 9. 500 mM imidazole eluate. (B) The 50 mM and the first two 100 mM imidazole
washes o f the Pro-Pol protein NT2 purification were pooled, dialvzed and incubated with
S-tag agarose. Fractions were subjected to electrophoresis through a 16% Tricine gel and
the proteins were detected by staining with Gelcode blue. Lane 1. N i'2 dialvsate. Lane 2.
pass. Lanes 3-5. sequential low salt washes. Lane 6, concentrated MgCL eluate. Lane
M, molecular weight markers. The position o f marker proteins are indicated at the sides.
The arrow points to the band at the correct size o f the Pro-Pol protein.
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FIG. 21. Purification o f histidine-linked HTLV-l protease on Ni‘:-NTA agarose. Lanes
AI and A2. 1st and 2nd Buffer A washes, respectively. Lane B. supernatant from Buffer
B wash. Lane P. pass. Lanes 1-3. 20 mM imidazole washes. Lane E. 1 M imidazole
eluate. Lane PPT. resuspended precipitate formed during dialysis. Lane R. refolded and
activated protease. Lane M. molecular weight markers. The position of marker proteins
are indicated at the sides. The arrow points to the histidine-linked protease.
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measurements o f the supernatant dialysate demonstrate that the protease is still active
with a specific activity =1.3 AAU p.L/pg«sec (Fig. 22). Contrary to the findings o f Ding
et al. (20). most o f the activity was found in the supernatant, not the white precipitate
(data not shown). However, our data does support the fact that the incomplete processing
o f the histidine tag from the protease fusion protein does not interfere with the activity o f
the enzyme (20).
CLEAVAGE PR O D U CT ANALYSIS
Months before the partial purification scheme o f the Pro-Pol protein was
established, HPLC analysis was attempted to separate the N i': affinity pool using a
reverse phase C 18 column. In using HPLC analysis. Pro-Pol protein, protease and
cleavage product peaks could be separated and evaluated individually. Regretfully, the
protein could not be recovered in an adequate quantity and the investigation was
terminated.
Fortunately, cleavage analysis o f the Pro-Pol protein does not require the protein
to be pure and the Pro-Pol protein from the N i': step and the final S-tag purification step
were cleaved with active protease. After an overnight incubation o f the Pro-Pol protein
with activated protease, the samples were analyzed by SDS-PAGE. Figure 23A shows
the results o f the cleavage o f the protein by the protease. The Pro-Pol protein appears as
a 12,000 Da band and the active protease appears as a 28,000 Da band. A diffuse protein
band at an approximate Mr=5.500. which was suspected to be a fragment o f the processed
Pro-Pol protein, only appears in the lane corresponding to the sample taken from the
cleavage reaction. The molecular weight o f the entire Pro-Pol protein is approximately
11,700 Da. Hydrolysis by HTLV-l protease at the putative cleavage site between Leu55
and Pro56 (numbered according to the amino acid sequence o f the Pro-Pol protein) would
produce 5.700 Da and 6.000 Da fragments. As shown in Fig. 23B. these same cleavage
samples were analyzed by immunoblotting with an antibody alkaline phosphatase
conjugate directed against the N-terminal 15 amino acid S-tag leader sequence fused to
the Pro-Pol protein. As shown in lane 2, the Pro-Pol protein construct reacted with the
antibody to give a band corresponding to the Mr = 12 kDa expected for the peptide.
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FIG. 22. Activity o f protease produced from the insoluble IK 19 construct. 200 pL o f the
dialysate o f the IK.19 protease construct was incubated in the presence o f a fluorescent,
synthetic substrate, in 100 mM sodium citrate buffer. pH 5.3. Excitation wavelength was
set at 320 nm/15 run bandpass.
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Fig. 23. Processing o f the Pro-Poi protein from the concentrated S-tag eluate by HTI.V-I
protease. Partially purified peptide samples were incubated with activated protease
overnight at 37°C. (A) SDS-PAGE was carried out as described in Materials and
Methods using a 10-20 % acrylamide gel which was stained with colloidal Coomassie
Blue, or (B) analyzed by Western blotting with an S-tag antibody alkaline phosphatase
conjugate. Lane 1, protease only control. Lane 2. Pro-Pol protein only control. Lane
cleavage reaction sample. Lane M, markers. The position o f marker proteins are
indicated at the sides.
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Similarly, both the 12 kDa band and the 5.5-kDa band were detected in the cleavage
product sample (Fig. 23B. lane 3). Neither the 12 kDa band nor the 5.5-kDa band was
detected in the protease only sample (Fig.23B, lane 1).

PROTEOLYTIC PROCESSING SITE ANALYSIS BY TRYPSIN DIGESTION
AND MASS SPECTROMETRY
To identify the location o f the proteolytic processing site of the N-terminus o f the
HTLV-l RT. several lanes were loaded with cleavage samples and a Pro-Pol protein
only sample on an 18% Tricine gel. The gel was stained with Colloidal Coomassie Blue
and sent to the Biomolecular Research Facility at the University o f Virginia in
Charlottesville. Virginia (Fig. 24). Dr. Nicholas Sherman removed the 5.5 kDa band,
digested it with trypsin, and the peptides were analyzed by mass spectrometry. Since
trypsin cleaves at the C-terminal side o f lysine and arginine residues (26), a list o f
possible peptides was generated from a hypothetical tryptic digestion o f the Pro-Pol
protein sequence as shown in Table V. A summary o f the seven fragments actually
recovered from the tryptic digestion o f the 5.5 kDa fragment is shown on the right-hand
side o f Table V. The actual spectra can be found in Appendix D. Five of the seven
peptides obtained from the tryptic digest o f the cleavage fragment matched those o f the
peptides calculated from the SEQUEST algorithm. Peptides 1 and 2 correspond to
sequences at the N-terminus of the Pro-Pol protein, while peptides 6 and 7 correspond to
sequences at the C-terminus.
Isolation o f only one fragment o f the Pro-Pol protein was expected to produce either
C-terminal or N-terminal peptides upon tryptic digestion. The fact that both N-terminal
and C-terminal peptides were obtained indicates the presence o f two protein bands, which
were previously identified as a single Pro-Pol protein fragment migrating at a distance of
5.500 Da. The total molecular weight o f the peptides found in the actual tryptic digest is
approximately 10,700 Da. almost twice the molecular weight o f the band that was
digested. Thus, analysis confirms that the diffuse band at Mr =5.500 Da was indeed the
two fragments o f the Pro-Pol protein predicted by cleavage at o r near the proteolytic
processing site identified by the sequence alignment.
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FIG . 24. SDS-PAGE gel sent for MS analysis. A 10-20 % acrylamide gel o f cleavage
samples either (A) stained with colloidal Coomassie Blue or (B) analyzed by Western
blotting with an S-tag antibody alkaline phosphatase conjugate. Lane I, Pro-Pol protein
only control. Lane 2, protease only control. Lanes 3-10, cleavage reaction samples.
Lane M, markers. The position o f marker proteins are indicated at the sides.
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TABLE V
Predicted and Actual Tryptic Peptides of Recombinant Pro-Pol protein
Predicted
Peptide

M,
(Da)

Actual
Sequence

Peptide
#

H
(Da)
(M+H

Charge
z

Sequence

+3
+2
+2
+1
+4
+2
+4

QHM DSPDQGTLVPR
GSM (o)AHGR

r
Glu3-Lys8
G in12-Arg25
Gin12-Arg25
Gly“ -A rg»
G ly^-A rg33
w ; - Lys;9
A sp -L y s
Gly^-Arg*3
L eu^-A rg92

590.7
1581.8
1597.8
805.0
821.0
1834.9
1848.1
3694.3
1078.3

ET A A A K
QH M DSPDQ G TLVPR
QH M (o)DSPDQG TLVPR
GSM AIIGR
G S M (o)A llG R
dalqqcqgvlylpeak

DALQ Q CQ G VLYLPEAK
GPPVILPIQAPAVLGLEHLPRPPE1SQFPLNPER
LQ ALQHLVR

1
2
3
4
5
6
7

1581.2
820.3
1833.1
595.3
3116.3
1077.6
1661.8

dalqqcqgvlylpeak

GPPVIL
P1QAPAVLGLEHLPRPPE1SQFPLNPER
LQALQHLVR
ALEAGHLEHHHHHH

Note: M(o)denotes oxidized Met. C denotes caiboxyamidomethyl Cys

-o
0\
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The identity o f the cleavage site location was determined by examination o f
peptides 4 and 5. neither o f which matches any o f the predicted peptides in Table V. The
mass spectra were determined manually. As shown in Figure 19. these peptide sequences
are located in the middle of the pro-pol amino acid sequence. The C-terminus o f
peptide is Leu3'w hile the N-terminus o f peptide 5 is Pro36. Cleavage at this position
could not have occurred by trypsin digestion since no lysine or arginine residues are
present.
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CHAPTER V
CONCLUSIONS

The collaborative activity o f the protease. reverse transcriptase and integrase enzymes
during retroviral replication ensures the survival o f the virion. The reverse transcriptase
catalyzes transcription o f viral RNA into double-stranded DNA. which is later
incorporated into the host to form the provirus. Structural information obtained about the
reverse transcriptase could aid in the development o f antiviral therapeutic agents aimed at
inhibiting the early onset of replication.
Unlike other retroviruses, little is known about the structure or proteolytic processing
o f the reverse transcriptase o f the human T-cell leukemia virus. In large part, this is due
to the fact that little reverse transcriptase is produced from the virus. The availability o f
methods to express foreign genes in E. coli facilitates isolation o f large quantities o f
recombinant reverse transcriptase. Although larger amounts o f total protein are recovered
by this method, the catalytic amount o f product still does not support serious biochemical
or biophysical investigations.
Two reports have been published on the expression o f recombinant HTLV-l RT. In
the first. Owen et al. expressed an enzymatically active HTLV-l RT in bacteria, and their
clone was created such that translation was initiated at Pro”. which is located within the
proposed pro-pol frameshift site (91). In the second report. Trentin et al. hypothesized
that the N-terminus of the RT should immediately follow the known C-terminus o f the
protease (131). The resulting protein from their construct also had RT activity (13).
However, they used an in vitro transcription/translation system that may have had an
impact on overall folding and potential subunit structure. Taken together, there are
discrepancies between the two published reports on recombinant HTLV-l RT.
Furthermore. Perach et al. (92) found that the amino acid sequence requirements and
molecular arrangements o f the recombinant BLV RT. the closest relative to HTLV. are
substantially different from those o f both HTLV-l RT studies. Here, a recombinant
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enzyme was also expressed in E.coli to further address the biochemical properties o f
HTLV-I RT as well as functional aspects o f protein-nucleic acid interactions.
By using sequence similarities with other retroviral reverse transcriptases in
conjunction with information about the location of the ribosomal frameshift. our
laboratory has cloned the correct coding region for the HTLV-l reverse transcriptase. To
our knowledge, this recombinant protein is the first reverse transcriptase activity
expressed from the CH strain o f H TLV -l.
In summary, a virtually homogenous, recombinant HTLV-l RT was separated from
E. coli proteins and enzyme degradation products by using a two-step chromatographic
technique. The purification scheme enhanced the presence o f the 99kDa band on SDSPAGE that corresponds to the predicted molecular weight o f the recombinant protein.
The size and activity o f the recombinant enzyme agree with the only published studies on
the protein purified from virus-infected human cell lines (101). Although the
recombinant protein is not stable for long periods o f time, it does maintain reverse
transcriptase activity throughout the purification process.
The purified recombinant HTLV-l RT was further characterized to determine its
primary structure. The primary structure o f proteins/peptides includes the determination
o f the linear order o f the amino acid residues, plus, any covalently attached groups and
the accurate measurement o f the protein's molecular weight. To date, the amino terminal
sequence of the polymerase gene o f H TLV -l. which encodes the reverse transcriptase,
had not been determined. The amino terminus of the reverse transcriptase may play a
role in the proper folding o f an active enzyme. For example, in the HIV-1 RT. the 20
amino-terminal amino acids are absolutely required for its polymerization (42).
Therefore, to confirm that the purified HTLV-l RT protein has the authentic Nterminus. identification o f the proteolytic processing site o f the Pro-Pol precursor protein
was determined. In the virion, the reverse transcriptase is released from the larger
polypeptide precursor by proteolytic cleavage. To mimic this proteolytic processing event
in vitro, the pro-pol cD N A , which spans the region where the HTLV-l protease is known
to terminate and continues 19 amino acids past the pro-pol frameshift, was cloned and
expressed in E. coli. The sequence o f the Pro-Pol protein contains a portion o f the larger
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Pro-Pol precursor and the putative protease cleavage site. Using an active HTLV-l
protease construct (Fig. 22), The protein was cleaved to produce a 5,500 Da cleavage
fragment (Fig. 23). LC/MS and MS-MS analysis of the cleavage fragment revealed that the
HTLV-l protease cleavage site which generates the N-terminus o f mature HTLV-l RT is
located between

L eu

^ ”7 ancj P ro ^ S jn ^

pro q r f

(82). 25 amino acids upstream o f the

pro-pol frameshift. This cleavage site does not differ from other retroviral processing
sites in the pol region (Table VI). which suggests that retroviral proteases preferentially
process their substrates at specific cleavage sites (20). The cleavage site is in agreement
with the sequence alignment perform by our group and by Trentin et al.(131).
Still, activity o f the purified enzyme is low (3.45 U/pg). Further efforts directed
towards improving the enrichment and optimal activity of the enzyme were not
successful. However, the low levels of activity observed are in agreement with those
reported by others (91). The overall inconsistency in activity measurements observed in
these different purification preparations may indicate that the RT activity o f HTLV-l in
and o f itself is low. or perhaps the presence of the T7 tag may have disrupted the
favorable native conformation of an active enzyme. Trentin et al. suggest that the
structure o f the HTLV-l RT is complex and thus a more detailed structural analysis is
necessary (131).
The low RT activity observed in this project provides useful information about the
biology o f the lymphotropic viruses. Reverse transcriptases lack editing functions and
have been shown to be error-prone in vitro. Therefore, these enzymes are presumed to
contribute to the high mutation rate in vivo (52). The frequency o f RT errors is dependent
on the source o f RT. For example, the error rate o f HIV-1 RT ranges from 1 in to 4000
7000 (per genome per cycle) while the error rates o f ASLV and MuLV are I in 9000 to
17.000 and 1 in 30.000. respectively (98. 104). This high level o f infidelity may be a
common characteristic o f RNA tumor virus reverse transcriptases.
High error rates in DNA replication result in genetically diverse populations o f
viruses. However, HTLV-l shows minimal strain variation in comparison to a much
greater variation seen among different isolates o f each lentivirus in the HTV/SIV family (28,
30, 57, 61, 77). Ratner et al.reports a 1.2%-3.3% nucleotide sequence difference among
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TABLE VI
Sequence o f Retroviral Protease Cleavage Sites in Their Respective PR/RT Junctions
Retrovirus

Sequence

HIV-1

Phe4-Pro

HIV-2

LeulPro

SIV-2

LeuiPro

BLV

GlyiVal

MuLV

LeuiThr

ALV

Leui-Thr

HTLV-l

LeuiPro
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HTLV-l isolates (97). The low activity o f the HTLV-l RT and apparent differences in
mutation rates may explain the genomic stability and replication mechanism o f H TL V -l.
Unlike the HTLV-l RT. HIV-1 RT is highly stable and has a much higher activity
(273.9 pmoles/pg/hr) in the presence o f a polv(rC)*oligo(dG) template (12). Chandra et al.
further reports the V,nax for HIV-l RT is seven-fold higher than the HTLV-l RT (12). Thus.
HIV-1 replicates persistently at a high level and quickly develops extensive within-isolate
sequence variation. It can be concluded, then, that there is little persistent replication o f
HTLV-l because the RT activity is low. Wodarz et al. suggests that the high viral load that
does exist during HTLV-l infection (0.1-10% o f peripheral blood mononuclear
lymphocytes), then, is maintained largely by division of pro virus-containing cells (145). In
short, the virus must rely on another replication mechanism, the mitotic route, to ensure its
survival. Wodarz et al. hypothesizes that mitotic division rather than infectious
transmission o f the virus produces most o f the newly infected cells. The mitotically
transmitted provirus is subsequently replicated by cellular DNA polymerases. The low
mutation rates o f HTLV-l are due to the proofreading capability o f cellular DNA
polymerases (145).
The results o f this research project have provided a basis for future structural
characterization o f retroviral reverse transcriptases. Tasara. et al. found significant
contributions of both the N- and C- termini o f the HIV-1 RT p 5 1 subunit to the structural
and functional conformation o f the p66 subunit, hence, the activity o f the HIV-1 RT
heterodimer (129). These regions contribute significantly to the maintenance of the
optimal conformation between the DNA polymerase and RNaseH catalytic sites o f the
p66 subunit. The authentic N-terminus o f HTLV-I RT was determined and confirmed in
this project. This information will. likewise, lead to a better understanding o f the proteinnucleic acid interactions o f this class o f enzymes. This research has also provided a basis
for future studies aimed at comparing the replication pathways addressed previously which
would lead to an increased understanding o f the pathogenesis o f HTLV-l induced diseases.
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1000000

y = 29853060.911 x (9 -395) r2 = 0.982

10000
1.5

1.75

2.5
Vo/Ve

FIG . 25. Standardization o f sepharose CL-6B gel filtration column (52 x 5 cm i.d.). The
ratio o f elution volumes (Vc) to the elution volume (V0) o f blue dextran (Mr= 2.000.000)
were plotted against the molecular weights o f the standards. Standards: (i-amylase (Mr=
200.000), alchohol dehydrogenase (Mr= 150.000). albumin (Mr = 66.000. carbonic
anvhydrase (Mr= 29.000 and cytochrome C ( Mr= 12.000)
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APPENDIX B
TABLE VII
Summary o f Preliminary Trials with Chromatographic Resins

Resin

Technique

Problems with Method

DEAE

anion exchanger

heparin
sepharose

pseudo-affinity

phenylsepharose

hydrophobic interaction

did not stick to co!umn:not much
cleanennever appeared on Western Blot

DNA cellulose

ligand affinity

did not appear on Western Blot; activity
dropped 6-fold

did not stick to column: pass fraction is
not very clean
inconsistency in results; activity drops
5-fold each preparation;does not
consistently appear in Western Blot
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A P P E N D IX C
Sequence of the Protease Construct
10

20

30

40

50

A CC G G G G G A G G T T T A A A C TCC CCC CCC A C A T T A CAG CAA G TC C T T C CT AAC CAA
T C C C C C C C T C C A A A T T G G A G G G G G G G G T G T A A T G TC G T T C A G G A A G G A T T G G T T
A rg

G ly

G ly

G lv

L eu

60

Thr

S er

Pro

70

Pro

Thr

L eu

80

G in

G in Val

90

L eu

Pro

Asn G in

100

G A C C T A G C A T C T A T T C T G C C A G T T A TA C C G T T A G A T C C C G C C C G T C G G C C C
C T G G A T C G T A G A T A A G A C G G T C A A T A T G G C A A T C TA G G G C G G G C A G C C G G G
A sp L eu A la S e r
lie
L eu Pro Val lie
Pro
L eu ’A sp Pro
A la A rg A rg
Pro

110

120

130

140

150

G TA A T T A AA G C C C A G G T T G A C ACC CAG A C C A G C CAC CCA A A G A C T A TC G A A G C T
C A T T A A T T T C G G G T C C A A C T G T G G G T C T G G T C G G TG G G T T T C T G A T A G C T T C G A
V al
lie
L ys A la
G in
V al A sp T h r G in T h r
S e r His Pro
L ys T h r He G lu A la

160

170

180

190

200

210

T T A C T A G A T A C A G G A G C A G A C A TG A CA G T C C T T C CA A TA G C C T T G T T C T C A A T T
A A T G A T CTA T G T C C T C G T CTG TAC TG T C A G G A A G G T TAT C G G A A C A AG A G T TTA
L eu

Leu

A sp T h r

G ly

220

A la A sp M et T h r

230

Val

Leu Pro

240

lie

A la L eu

250

Phe

S er A sn

260

A A T A C T C CC C TC A A A G A C ACA TCC G TA T TG G G G GCA GGA G G C C A A A CC CA A G A T
TTA T G A GGG G A G T T T CTG T G T AGG C A T A A C C C C CGT CCT C C G G T T TGG G T T CTA
A sn T h r
Pro L eu L ys
A sp T h r S er V al L eu
G ly A la G ly
G ly G in
T h r G in A sp

270

280

290

300

310

320

C A C T T T A A G C T C A C C T C C C T T C C T G T G C T A A T A C G C C TC C C T T T C C G G A C A A C G
GTG A A A TTC G A G T G G A G G GAA GGA CAC G A T TA T GCG GAG G G A A AG G CC T G T TG C
H is P he L y s L eu T h r S e r Leu Pro V al L eu
lie A rg Leu P ro P h e A rg T h r T h r

330

340

350

360

370

C C T A T T G T T T T A A C A T C T T G C C TA G T T G A T A C C A A A A A C A A C T G G G C C A T C A T A
G G A T A A C A A A A T T G T A G A A C G G A T C A A C T A T G G T T T T TG T T G A C C C G G T A G T A T
Pro
He V al L eu T h r S e r C ys Leu V al A sp T h r Lys Asn A sn T rp A la
He He

380

390

400

410

420

G G T C G T G A T G C C T T A C A A C A A T G C C A A G G C G T C C TG T A C C T C C C T G A G G C A A A A
C C A G C A C T A C G G A A T G T T G T T A C G G T T C C G C A G G A C A TG G A G G G A C TC C G T T T T
G ly A rg A sp A la Leu G in G in C y s G in G ly V al Leu T v r L eu P ro G lu A la Lys

430

440

450

460

470

480

A G G C C G C C T G T A A T C T T G C C A A T A C A G G C G C C A G C C G TC C T T G G C C T A G A A
TCC G G C G G A C A T TA G A A C G G T TA T GTC C G C G G T CGG CAG G A A C C G G A T C TT
A rg P ro
Pro V al He L eu Pro He G in A la P ro A la Val L eu G ly Leu G lu

FIG. 26. Protease construct created by amplifying the pro ORF from pRCH. Primers
were chosen to create unique Ndel and Bam HI sites to allow subsequent cloning in
frame with the N-terminal His tag coding sequence.
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APPENDIX D
Mass Spectra of Actual Peptides from Pro-Pol Fragment
597.5

100-g

Peptide 1
QHMDSPDQGTLVPR
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Fig. 27. MS analysis of Peptide latter tryptic digestion of Pro-Pol protein fragment. The Mr of the sequence, QHMDSPDQGTLVPR,
is 1581.2 daltons.
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Fig. 28. MS analysis of Peptide 2 after tryptic digestion of Pro-Pol protein fragment. The Mr of the sequence, GSM(o)AKIIGR, is
820.3 daltons.
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Fig. 29. MS analysis o f Peptide 3 after tryptic digestion of Pro-Pol protein fragment. The Mr of the sequence,
DALQQCQGVLYLPEAK, is 1833.1 daltons.
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APPENDIX D, Continued
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Peptide 4
GPPVIL
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Fig. 30. MS analysis of Peptide 5 after tryptic digestion of Pro-Pol protein fragment. The Mr of the sequence. GPPVIL, is 595 .3
daltons.
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APPENDIX D, Continued
904. 97p

Peptide 5
PIQAPAVLGLEHLPRPPEISQFPLNPER
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Fig. 31. MS analysis of Peptide 5 after tryptic digestion of Pro-Pol protein fragment. The Mr of the sequence,
PIQAPAVLGLEHLPRPPEISQFPLNPER, is 3116.3 daltons
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Peptide 6
LQALQHLVR
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Fig. 32. MS analysis o f Peptide 6 after tryptic digestion of Pro-Pol protein fragment. The Mr of the sequence, LQALGHLVR, is
1077.6.
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APPENDIX D, Continued
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Peptide 7
ALEAGHLEHHHHHH
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Fig. 33. MS analysis of Peptide latter tryptic digestion of Pro-Pol protein fragment. The Mr of the sequence,
ALEAGHLEHHHHHH is 1661.8 daltons.
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